{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:45:31Z","timestamp":1791945931361,"version":"4.3.4"},"reference-count":257,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T00:00:00Z","timestamp":1745366400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s13346-025-01863-3","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T12:08:08Z","timestamp":1745410088000},"page":"825-854","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Emerging nano-derived therapy for the treatment of dementia: a comprehensive review"],"prefix":"10.1007","volume":"16","author":[{"given":"Shadaan","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubna","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Adil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritu","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saara","family":"khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0785-1735","authenticated-orcid":false,"given":"Nazeer","family":"Hasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd.","family":"Aqil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,23]]},"reference":[{"key":"1863_CR1","unstructured":"Arnulf I, Leu S, Oudiette D. Abnormal sleep and sleepiness in Parkinson\u2019s disease."},{"key":"1863_CR2","doi-asserted-by":"publisher","unstructured":"Mayeux R, Stern Y. Epidemiology of Alzheimer disease. Cold spring harbor perspectives in medicine. 2012;2(8):a006239. https:\/\/doi.org\/10.1101\/cshperspect.a006239","DOI":"10.1101\/cshperspect.a006239"},{"issue":"7","key":"1863_CR3","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1080\/03007995.2022.2059978","volume":"38","author":"U Desai","year":"2022","unstructured":"Desai U, Chandler J, Kirson N, Georgieva M, Ching H, Westermeyer B, et al. Epidemiology and economic burden of lewy body dementia in the united States. Curr Med Res Opin. 2022;38(7):1177\u201388.","journal-title":"Curr Med Res Opin"},{"key":"1863_CR4","doi-asserted-by":"publisher","unstructured":"Lampropoulos IC, Malli F, Sinani O, Gourgoulianis KI, Xiromerisiou G. Worldwide trends in mortality related to Parkinson's disease in the period of 1994\u20132019: Analysis of vital registration data from the WHO Mortality Database. Frontiers in neurology. 2022;13:956440. https:\/\/doi.org\/10.3389\/fneur.2022.956440","DOI":"10.3389\/fneur.2022.956440"},{"issue":"7","key":"1863_CR5","doi-asserted-by":"publisher","first-page":"5629","DOI":"10.1007\/s11033-021-06512-9","volume":"48","author":"T Athar","year":"2021","unstructured":"Athar T, Balushi K, Al, Alam S, Cholinesterase C. Recent advances on drug development and emerging therapeutic agents for alzheimer\u2019s disease. Mol Biol Rep. 2021;48(7):5629\u201345.","journal-title":"Mol Biol Rep"},{"key":"1863_CR6","doi-asserted-by":"publisher","unstructured":"Lee J, Meijer E, Langa KM, Ganguli M, Varghese M, Banerjee J, et al. Prevalence of dementia in India: national and state estimates from a nationwide study. Alzheimers dement. 2023;19(7):2898\u20132912. https:\/\/doi.org\/10.1002\/alz.12928","DOI":"10.1002\/alz.12928"},{"issue":"9","key":"1863_CR7","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jamaneurol.2017.1359","volume":"74","author":"MM Mielke","year":"2017","unstructured":"Mielke MM, Hagen CE, Wennberg AMV, Airey DC, Savica R, Knopman DS, et al. Association of plasma total Tau level with cognitive decline and risk of mild cognitive impairment or dementia in the Mayo clinic study on aging. JAMA Neurol. 2017;74(9):1073\u201380.","journal-title":"JAMA Neurol"},{"issue":"11","key":"1863_CR8","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1212\/WNL.0b013e3181b78448","volume":"73","author":"JC Lambert","year":"2009","unstructured":"Lambert JC, Schraen-Maschke S, Richard F, Fievet N, Rouaud O, Berr C, et al. Association of plasma amyloid \u0392 with risk of dementia: the prospective Three-City study. Neurology. 2009;73(11):847\u201353.","journal-title":"Neurology"},{"issue":"10","key":"1863_CR9","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.amjmed.2018.01.022","volume":"131","author":"SA Gale","year":"2018","unstructured":"Gale SA, Acar D, Daffner KR. Dement Am J Med. 2018;131(10):1161\u20139.","journal-title":"Dement Am J Med"},{"key":"1863_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.phrs.2019.01.009","volume":"141","author":"E Brook","year":"2019","unstructured":"Brook E, Mamo J, Wong R, Al-Salami H, Falasca M, Lam V, et al. Blood-brain barrier disturbances in diabetes-associated dementia: therapeutic potential for cannabinoids. Pharmacol Res. 2019;141:291\u20137.","journal-title":"Pharmacol Res"},{"key":"1863_CR11","doi-asserted-by":"crossref","unstructured":"Kuruppu DK, Matthews BR. Young-Onset Dementia. 2013.","DOI":"10.1055\/s-0033-1359320"},{"issue":"6","key":"1863_CR12","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1177\/0706743719892717","volume":"65","author":"A Bahji","year":"2020","unstructured":"Bahji A, Meyyappan AC, Hawken ER. Cannabinoids for the neuropsychiatric symptoms of dementia: A systematic review and Meta-Analysis. Can J Psychiatry. 2020;65(6):365\u201376.","journal-title":"Can J Psychiatry"},{"issue":"6","key":"1863_CR13","first-page":"1","volume":"10","author":"G Abate","year":"2021","unstructured":"Abate G, Uberti D, Tambaro S. Potential and limits of cannabinoids in Alzheimer\u2019s disease therapy. Biology (Basel). 2021;10(6):1\u201321.","journal-title":"Biology (Basel)"},{"issue":"1","key":"1863_CR14","first-page":"81","volume":"23","author":"J Weber","year":"2009","unstructured":"Weber J, Keating GM. Ropinirole prolonged release. Adv Parkinson\u2019S Disease. 2009;23(1):81\u201390.","journal-title":"Adv Parkinson \u2019 S Disease"},{"key":"1863_CR15","doi-asserted-by":"publisher","first-page":"204209861984699","DOI":"10.1177\/2042098619846993","volume":"10","author":"JB Hillen","year":"2019","unstructured":"Hillen JB, Soulsby N, Alderman C, Caughey GE. Safety and effectiveness of cannabinoids for the treatment of neuropsychiatric symptoms in dementia: a systematic review. Ther Adv Drug Saf. 2019;10:204209861984699.","journal-title":"Ther Adv Drug Saf"},{"issue":"3","key":"1863_CR16","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1093\/brain\/awt355","volume":"137","author":"U Tr\u00e4ger","year":"2014","unstructured":"Tr\u00e4ger U, Andre R, Lahiri N, Magnusson-Lind A, Weiss A, Grueninger S, et al. HTT-lowering reverses Huntington\u2019s disease immune dysfunction caused by NF\u03baB pathway dysregulation. Brain. 2014;137(3):819\u201333.","journal-title":"Brain"},{"issue":"2","key":"1863_CR17","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1212\/01.wnl.0000194318.74946.b6","volume":"66","author":"SM Hersch","year":"2006","unstructured":"Hersch SM, Gevorkian S, Marder K, Moskowitz C, Feigin A, Cox M, et al. Creatine in huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2\u2019dG. Neurology. 2006;66(2):250\u20132.","journal-title":"Neurology"},{"issue":"1","key":"1863_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","volume":"10","author":"CA Ross","year":"2011","unstructured":"Ross CA, Tabrizi SJ. Huntington\u2019s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10(1):83\u201398.","journal-title":"Lancet Neurol"},{"issue":"4","key":"1863_CR19","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/ana.410420411","volume":"42","author":"E Sapp","year":"1997","unstructured":"Sapp E, Schwarz C, Chase K, Bhide PG, Young AB, Penney J, et al. Huntingtin localization in brains of normal and Huntington\u2019s disease patients. Ann Neurol. 1997;42(4):604\u201312.","journal-title":"Ann Neurol"},{"issue":"14","key":"1863_CR20","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1093\/hmg\/ddh162","volume":"13","author":"YS Choo","year":"2004","unstructured":"Choo YS, Johnson GVW, MacDonald M, Detloff PJ, Lesort M. Mutant Huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome C release. Hum Mol Genet. 2004;13(14):1407\u201320.","journal-title":"Hum Mol Genet"},{"issue":"3","key":"1863_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrneurol.2017.188","volume":"14","author":"MD Sweeney","year":"2018","unstructured":"Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018;14(3):133\u201350.","journal-title":"Nat Rev Neurol"},{"key":"1863_CR22","doi-asserted-by":"crossref","unstructured":"Al-Qazzaz NK, Ali SHBM, Ahmad SA, Chellappan K, Islam MS, Escudero J. Role of EEG as biomarker in the early detection and classification of dementia. Sci World J. 2014;2014.","DOI":"10.1155\/2014\/906038"},{"key":"1863_CR23","doi-asserted-by":"crossref","unstructured":"Papaliagkas V, Kalinderi K, Vareltzis P, Moraitou D, Papamitsou T, Chatzidimitriou M. CSF biomarkers in the early diagnosis of mild cognitive impairment and Alzheimer\u2019s disease. Int J Mol Sci. 2023;24(10).","DOI":"10.3390\/ijms24108976"},{"issue":"3","key":"1863_CR24","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1080\/15622970701535502","volume":"9","author":"BSO Diniz","year":"2008","unstructured":"Diniz BSO, Pinto JA, Forlenza OV. Do CSF total Tau, phosphorylated Tau, and b-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer\u2019s disease? A systematic review and meta-analysis of the literature. World J Biol Psychiatry. 2008;9(3):172\u201382.","journal-title":"World J Biol Psychiatry"},{"issue":"155","key":"1863_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.neubiorev.2019.04.014","volume":"102","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Xin Y, Meng S, He Z, Hu W. Neurofilament light chain protein in neurodegenerative dementia: A systematic review and network meta-analysis. Neurosci Biobehav Rev. 2019;102(155):123\u201338.","journal-title":"Neurosci Biobehav Rev"},{"issue":"3","key":"1863_CR26","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1136\/jnnp-2013-307454","volume":"86","author":"J Kuhle","year":"2015","unstructured":"Kuhle J, Gaiottino J, Leppert D, Petzold A, Bestwick JP, Malaspina A, et al. Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome. J Neurol Neurosurg Psychiatry. 2015;86(3):273\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"1863_CR27","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/acn3.325","volume":"3","author":"LH Meeter","year":"2016","unstructured":"Meeter LH, Dopper EG, Jiskoot LC, Sanchez-Valle R, Graff C, Benussi L, et al. Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol. 2016;3(8):623\u201336.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"1863_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuron.2016.06.030","volume":"91","author":"H Zetterberg","year":"2016","unstructured":"Zetterberg H. Neurofilament light: A dynamic Cross-Disease fluid biomarker for neurodegeneration. Neuron. 2016;91(1):1\u20133.","journal-title":"Neuron"},{"issue":"4","key":"1863_CR29","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1001\/jama.2009.1064","volume":"302","author":"N Mattsson","year":"2009","unstructured":"Mattsson N, Ewers M, Rich K, Kaiser E, Mulugeta E, Rose E. CSF biomarkers and incipient alzheimer disease. JAMA. 2009;302(4):385\u201393.","journal-title":"JAMA"},{"key":"1863_CR30","doi-asserted-by":"crossref","unstructured":"Dhiman K, Villemagne VL, Fowler C, Bourgeat P, Li QX, Collins S et al. Cerebrospinal fluid neurofilament light predicts risk of dementia onset in cognitively healthy individuals and rate of cognitive decline in mild cognitive impairment: A prospective longitudinal study. Biomedicines. 2022;10(5).","DOI":"10.3390\/biomedicines10051045"},{"key":"1863_CR31","doi-asserted-by":"publisher","unstructured":"Gaur A, Gallagher D, Herrmann N, Chen JJ, Marzolini S, Oh P, et al. Neurofilament light chain as a biomarker of global cognition in individuals with possible vascular mild cognitive impairment. J Geriatr Psychiatry Neurol. 2025;38(1):62\u201372. https:\/\/doi.org\/10.1177\/08919887241254469","DOI":"10.1177\/08919887241254469"},{"key":"1863_CR32","doi-asserted-by":"publisher","unstructured":"Arslan B, Zetterberg H, Ashton NJ. Blood-based biomarkers in Alzheimer's disease - moving towards a new era of diagnostics. Clin Chem Lab Med. 2024;62(6):1063\u201369. https:\/\/doi.org\/10.1515\/cclm-2023-1434","DOI":"10.1515\/cclm-2023-1434"},{"issue":"11","key":"1863_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm9113452","volume":"9","author":"K Wilczy\u0144ska","year":"2020","unstructured":"Wilczy\u0144ska K, Waszkiewicz N. Diagnostic utility of selected serum dementia biomarkers: amyloid \u03b2-40, amyloid \u0392 -42, Tau protein, and YKL-40: A review. J Clin Med. 2020;9(11):1\u201326.","journal-title":"J Clin Med"},{"key":"1863_CR34","doi-asserted-by":"publisher","unstructured":"Chun KA. Beta-amyloid imaging in dementia. J Yeungnam Med Sci. 2018;35(1):1\u20136. https:\/\/doi.org\/10.12701\/yujm.2018.35.1.1","DOI":"10.12701\/yujm.2018.35.1.1"},{"key":"1863_CR35","doi-asserted-by":"publisher","unstructured":"Hilal S, Wolters FJ, Verbeek MM, Vanderstichele H, Ikram MK, Stoops E, et al. Plasma amyloid-\u03b2 levels, cerebral atrophy and risk of dementia: a population-based study. Alzheimers Res Ther. 2018;10(1):63. https:\/\/doi.org\/10.1186\/s13195-018-0395-6","DOI":"10.1186\/s13195-018-0395-6"},{"issue":"1","key":"1863_CR36","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1001\/jamapsychiatry.2017.3391","volume":"75","author":"WJ Jansen","year":"2018","unstructured":"Jansen WJ, Ossenkoppele R, Tijms BM, Fagan AM, Hansson O, Klunk WE, et al. Association of cerebral amyloid-\u03b2 aggregation with cognitive functioning in persons without dementia. JAMA Psychiatry. 2018;75(1):84\u201395.","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"1863_CR37","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/WAD.0b013e318260a8cb","volume":"27","author":"AL Metti","year":"2013","unstructured":"Metti AL, Cauley JA, Ayonayon HN, Harris TB, Rosano C, Williamson JD, et al. The demographic and medical correlates of plasma A\u03b240 and A\u03b242. Alzheimer Dis Assoc Disord. 2013;27(3):244\u20139.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"5","key":"1863_CR38","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jalz.2015.10.009","volume":"12","author":"F Llorens","year":"2016","unstructured":"Llorens F, Schmitz M, Karch A, Cramm M, Lange P, Gherib K, et al. Comparative analysis of cerebrospinal fluid biomarkers in the differential diagnosis of neurodegenerative dementia. Alzheimer\u2019s Dement. 2016;12(5):577\u201389.","journal-title":"Alzheimer\u2019s Dement"},{"key":"1863_CR39","first-page":"179","volume":"8","author":"N Fandos","year":"2017","unstructured":"Fandos N, P\u00e9rez-Grijalba V, Pesini P, Olmos S, Bossa M, Villemagne VL, et al. Plasma amyloid \u0392 42\/40 ratios as biomarkers for amyloid \u0392 cerebral deposition in cognitively normal individuals. Alzheimer\u2019s Dement Diagnosis Assess Dis Monit. 2017;8:179\u201387.","journal-title":"Alzheimer\u2019s Dement Diagnosis Assess Dis Monit"},{"key":"1863_CR40","unstructured":"Cheng YW, Lin YJ, Lin YS, Hong WP, Kuan YC, Wu KY et al. Application of blood-based biomarkers of Alzheimer\u2019s disease in clinical practice: recommendations from Taiwan dementia society. J Formos Med Assoc. 2024;(May 2023)."},{"key":"1863_CR41","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.neulet.2014.01.014","volume":"565","author":"AM Colangelo","year":"2014","unstructured":"Colangelo AM, Alberghina L, Papa M. Astrogliosis as a therapeutic target for neurodegenerative diseases. Neurosci Lett. 2014;565:59\u201364.","journal-title":"Neurosci Lett"},{"issue":"1","key":"1863_CR42","doi-asserted-by":"publisher","first-page":"48","DOI":"10.15252\/emmm.201708202","volume":"10","author":"ME Umoh","year":"2018","unstructured":"Umoh ME, Dammer EB, Dai J, Duong DM, Lah JJ, Levey AI, et al. A proteomic network approach across the ALS - FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain. EMBO Mol Med. 2018;10(1):48\u201362.","journal-title":"EMBO Mol Med"},{"issue":"6","key":"1863_CR43","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.immuni.2017.06.006","volume":"46","author":"SA Liddelow","year":"2017","unstructured":"Liddelow SA, Barres BA. Reactive astrocytes: production, function, and therapeutic potential. Immunity. 2017;46(6):957\u201367.","journal-title":"Immunity"},{"key":"1863_CR44","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.pneurobio.2016.01.001","volume":"144","author":"LM Osborn","year":"2016","unstructured":"Osborn LM, Kamphuis W, Wadman WJ, Hol EM. Astrogliosis: an integral player in the pathogenesis of Alzheimer\u2019s disease. Prog Neurobiol. 2016;144:121\u201341.","journal-title":"Prog Neurobiol"},{"issue":"3","key":"1863_CR45","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1136\/jnnp-2019-321954","volume":"91","author":"C Heller","year":"2020","unstructured":"Heller C, Foiani MS, Moore K, Convery R, Bocchetta M, Neason M, et al. Plasma glial fibrillary acidic protein is Raised in progranulin-associated frontotemporal dementia. J Neurol Neurosurg Psychiatry. 2020;91(3):263\u201370.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"1863_CR46","first-page":"1","volume":"13","author":"C Cicognola","year":"2021","unstructured":"Cicognola C, Janelidze S, Hertze J, Zetterberg H, Blennow K, Mattsson-Carlgren N, et al. Plasma glial fibrillary acidic protein detects alzheimer pathology and predicts future conversion to alzheimer dementia in patients with mild cognitive impairment. Alzheimer\u2019s Res Ther. 2021;13(1):1\u20139.","journal-title":"Alzheimer\u2019s Res Ther"},{"issue":"November","key":"1863_CR47","first-page":"1","volume":"12","author":"JR Hall","year":"2021","unstructured":"Hall JR, Petersen M, Johnson L, O\u2019Bryant SE. Plasma total Tau and neurobehavioral symptoms of cognitive decline in cognitively normal older adults. Front Psychol. 2021;12(November):1\u20137.","journal-title":"Front Psychol"},{"key":"1863_CR48","doi-asserted-by":"crossref","unstructured":"Ricci M, Cimini A, Camedda R, Chiaravalloti A, Schillaci O. Tau biomarkers in dementia: positron emission tomography radiopharmaceuticals in tauopathy assessment and future perspective. Int J Mol Sci. 2021;22(23).","DOI":"10.3390\/ijms222313002"},{"issue":"3","key":"1863_CR49","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1093\/brain\/awaa054","volume":"143","author":"F de Wolf","year":"2020","unstructured":"de Wolf F, Ghanbari M, Licher S, McRae-McKee K, Gras L, Weverling GJ, et al. Plasma total Tau and neurobehavioral symptoms of cognitive decline in cognitively normal older adults. Brain. 2020;143(3):1220\u201332.","journal-title":"Brain"},{"issue":"5","key":"1863_CR50","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1001\/jamaneurol.2018.4666","volume":"76","author":"MP Pase","year":"2019","unstructured":"Pase MP, Beiser AS, Himali JJ, Satizabal CL, Aparicio HJ, Decarli C, et al. Assessment of plasma total Tau level as a predictive biomarker for dementia and related endophenotypes. JAMA Neurol. 2019;76(5):598\u2013606.","journal-title":"JAMA Neurol"},{"issue":"June","key":"1863_CR51","first-page":"1","volume":"13","author":"JA Pillai","year":"2021","unstructured":"Pillai JA, Khrestian M, Bena J, Leverenz JB, Bekris LM. Temporal ordering of inflammatory analytes sTNFR2 and sTREM2 in relation to Alzheimer\u2019s disease biomarkers and clinical outcomes. Front Aging Neurosci. 2021;13(June):1\u201314.","journal-title":"Front Aging Neurosci"},{"issue":"6","key":"1863_CR52","doi-asserted-by":"publisher","first-page":"595","DOI":"10.15252\/emmm.201606210","volume":"8","author":"F Durst","year":"2016","unstructured":"Durst F, Tropea C. The amyloid hypothesis of Alzheimer\u2019s disease at 25 years. EMBO Mol Med. 2016;8(6):595\u2013608.","journal-title":"EMBO Mol Med"},{"issue":"9","key":"1863_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15252\/emmm.202012308","volume":"12","author":"M Ewers","year":"2020","unstructured":"Ewers M, Biechele G, Su\u00e1rez-Calvet M, Sacher C, Blume T, Morenas\u2010Rodriguez E, et al. Higher CSF sTREM2 and microglia activation are associated with slower rates of beta\u2010amyloid accumulation. EMBO Mol Med. 2020;12(9):1\u201314.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"1863_CR54","first-page":"1","volume":"16","author":"Y Wang","year":"2024","unstructured":"Wang Y, Ye M, Ji Q, Liu Q, Xu X, Zhan Y. The longitudinal trajectory of CSF sTREM2: the Alzheimer\u2019s disease neuroimaging initiative. Alzheimer\u2019s Res Ther. 2024;16(1):1\u201311.","journal-title":"Alzheimer\u2019s Res Ther"},{"key":"1863_CR55","doi-asserted-by":"publisher","unstructured":"Su\u00e1rez-Calvet M, Kleinberger G, Araque Caballero M\u00c1, Brendel M, Rominger A, Alcolea D, et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. EMBO Mol Med. 2016;8(5):466\u2013476. https:\/\/doi.org\/10.15252\/emmm.201506123","DOI":"10.15252\/emmm.201506123"},{"issue":"S6","key":"1863_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/alz.061230","volume":"18","author":"E Morenas-Rodriguez","year":"2022","unstructured":"Morenas-Rodriguez E, Haass C, Network DIA. Longitudinal increase of sTREM2 in CSF and its relationship with other biomarkers and cognition along the evolution of autosomal dominant Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2022;18(S6):1\u20132.","journal-title":"Alzheimer\u2019s Dement"},{"issue":"1","key":"1863_CR57","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/acn3.266","volume":"3","author":"S Janelidze","year":"2016","unstructured":"Janelidze S, Hertze J, Zetterberg H, Landqvist Wald\u00f6 M, Santillo A, Blennow K, et al. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer\u2019s disease. Ann Clin Transl Neurol. 2016;3(1):12\u201320.","journal-title":"Ann Clin Transl Neurol"},{"issue":"8","key":"1863_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0135458","volume":"10","author":"M Wennstr\u00f6m","year":"2015","unstructured":"Wennstr\u00f6m M, Surova Y, Hall S, Nilsson C, Minthon L, Hansson O, et al. The inflammatory marker YKL-40 is elevated in cerebrospinal fluid from patients with Alzheimer\u2019s but not Parkinson\u2019s disease or dementia with lewy bodies. PLoS ONE. 2015;10(8):1\u201313.","journal-title":"PLoS ONE"},{"issue":"1","key":"1863_CR59","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.exger.2009.09.008","volume":"45","author":"A Cedazo-Minguez","year":"2010","unstructured":"Cedazo-Minguez A, Winblad B. Biomarkers for Alzheimer\u2019s disease and other forms of dementia: clinical needs, limitations and future aspects. Exp Gerontol. 2010;45(1):5\u201314.","journal-title":"Exp Gerontol"},{"issue":"2","key":"1863_CR60","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","volume":"9","author":"CC Liu","year":"2013","unstructured":"Liu CC, Kanekiyo T, Xu HBG. Nat Rev Neurol Nat Rev Neurosci. 2013;9(2):106\u201318.","journal-title":"Nat Rev Neurol Nat Rev Neurosci"},{"issue":"2","key":"1863_CR61","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.bgm.2014.11.001","volume":"7","author":"A Jagtap","year":"2015","unstructured":"Jagtap A, Gawande S, Sharma S. Biomarkers in vascular dementia: A recent update. Biomarkers Genomic Med. 2015;7(2):43\u201356.","journal-title":"Biomarkers Genomic Med"},{"issue":"6","key":"1863_CR62","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1212\/CON.0000000000001505","volume":"30","author":"SW Scholz","year":"2024","unstructured":"Scholz SW, Cobos I. Genetics and neuropathology of neurodegenerative dementias. Contin Lifelong Learn Neurol. 2024;30(6):1801\u201322.","journal-title":"Contin Lifelong Learn Neurol"},{"issue":"SUPPL 3","key":"1863_CR63","doi-asserted-by":"publisher","first-page":"341","DOI":"10.3233\/JAD-2006-9S338","volume":"9","author":"A Goate","year":"2006","unstructured":"Goate A. Segregation of a missense mutation in the amyloid \u03b2-protein precursor gene with Familial Alzheimer\u2019s disease. J Alzheimer\u2019s Dis. 2006;9(SUPPL 3):341\u20137.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1863_CR64","first-page":"1163","volume":"10","author":"Y Cai","year":"2015","unstructured":"Cai Y, An SSA, Kim S. Mutations in presenilin 2 and its implications in Alzheimer\u2019s disease and other dementia-associated disorders. Clin Interv Aging. 2015;10:1163\u201372.","journal-title":"Clin Interv Aging"},{"issue":"1","key":"1863_CR65","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.stemcr.2013.04.001","volume":"1","author":"C Gomez","year":"2013","unstructured":"Gomez C, Chua W, Miremadi A, Quist S, Headon DJ, Watt FM. Stem Cell Rep Stem Cell Rep. 2013;1(1):19\u201327.","journal-title":"Stem Cell Rep Stem Cell Rep"},{"issue":"3","key":"1863_CR66","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1001\/jamaneurol.2013.6002","volume":"71","author":"E Devenney","year":"2014","unstructured":"Devenney E, Hornberger M, Irish M, Mioshi E, Burrell J, Tan R, et al. Frontotemporal dementia associated with the C9ORF72 mutation: A unique clinical profile. JAMA Neurol. 2014;71(3):331\u20139.","journal-title":"JAMA Neurol"},{"issue":"5380","key":"1863_CR67","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1126\/science.281.5380.1188","volume":"281","author":"AD Wagner","year":"1998","unstructured":"Wagner AD, Schacter DL, Rotte M, Koutstaal W, Maril A, Dale AM, et al. Building memories: remembering and forgetting of verbal experiences as predicted by brain activity. Sci (80-). 1998;281(5380):1188\u201391.","journal-title":"Sci (80-)"},{"issue":"10","key":"1863_CR68","doi-asserted-by":"publisher","first-page":"4084","DOI":"10.1038\/s41380-023-02215-8","volume":"28","author":"L Chouliaras","year":"2023","unstructured":"Chouliaras L, O\u2019Brien JT. The use of neuroimaging techniques in the early and differential diagnosis of dementia. Mol Psychiatry. 2023;28(10):4084\u201397.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"1863_CR69","first-page":"82","volume":"8","author":"MC Tartaglia","year":"2011","unstructured":"Tartaglia MC, Rosen HJ, Miller BL. Neuroimaging Dement Neurother. 2011;8(1):82\u201392.","journal-title":"Neuroimaging Dement Neurother"},{"issue":"1","key":"1863_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12974-023-02796-9","volume":"20","author":"YS Hok-A-Hin","year":"2023","unstructured":"Hok-A-Hin YS, del Campo M, Boiten WA, Stoops E, Vanhooren M, Lemstra AW, et al. Neuroinflammatory CSF biomarkers MIF, sTREM1, and sTREM2 show dynamic expression profiles in Alzheimer\u2019s disease. J Neuroinflammation. 2023;20(1):1\u201310.","journal-title":"J Neuroinflammation"},{"issue":"1","key":"1863_CR71","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2217\/nmt-2020-0048","volume":"11","author":"G Gopalakrishna","year":"2021","unstructured":"Gopalakrishna G, Srivathsal Y, Kaur G. Cannabinoids in the management of frontotemporal dementia: A case series. Neurodegener Dis Manag. 2021;11(1):61\u20134.","journal-title":"Neurodegener Dis Manag"},{"issue":"6","key":"1863_CR72","first-page":"1072","volume":"26","author":"O Rascol","year":"2011","unstructured":"Rascol O, Lozano A, Stern M, Poewe W. Milestones in Parkinson\u2019s disease therapeutics milestones in the medical management of Parkinson \u2019. S Disease. 2011;26(6):1072\u201382.","journal-title":"S Disease"},{"key":"1863_CR73","doi-asserted-by":"publisher","unstructured":"Mok PL H, Carr MJ, Guthrie B, Morales DR, Sheikh A, Elliott RA et al. Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study. BMJ. 2024;385:e076268. https:\/\/doi.org\/10.1136\/bmj-2023-076268","DOI":"10.1136\/bmj-2023-076268"},{"issue":"1","key":"1863_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1471-4159.2005.03530.x","volume":"96","author":"PH Reddy","year":"2006","unstructured":"Reddy PH. Amyloid precursor protein-mediated free radicals and oxidative damage: implications for the development and progression of Alzheimer\u2019s disease. J Neurochem. 2006;96(1):1\u201313.","journal-title":"J Neurochem"},{"key":"1863_CR75","doi-asserted-by":"crossref","unstructured":"Woo Y, Hyun MK. Effectiveness of Integrative Therapy for Parkinson\u2019s Disease Management. 2019;11(February):1\u20139.","DOI":"10.3389\/fnagi.2019.00040"},{"key":"1863_CR76","doi-asserted-by":"publisher","first-page":"112163","DOI":"10.1016\/j.ejmech.2020.112163","volume":"192","author":"H Li","year":"2020","unstructured":"Li H, Liu Y, Tian D, Tian L, Ju X, Qi L, et al. Overview of Cannabidiol (CBD) and its analogues: structures, biological activities, and neuroprotective mechanisms in epilepsy and Alzheimer\u2019s disease. Eur J Med Chem. 2020;192:112163.","journal-title":"Eur J Med Chem"},{"key":"1863_CR77","doi-asserted-by":"publisher","first-page":"106318","DOI":"10.1016\/j.jddst.2024.106318","volume":"102","author":"M Adil","year":"2024","unstructured":"Adil M, Jiba U, Khan A, Shahrukh M, Hasan N, Ahmad FJ. Advancements in ischemic stroke management: transition from traditional to Nanotechnological approaches. J Drug Deliv Sci Technol. 2024;102:106318.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"4","key":"1863_CR78","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1590\/1980-57642016dn11-040005","volume":"11","author":"N Custodio","year":"2017","unstructured":"Custodio N, Montesinos R, Lira D, Herrera-P\u00e9rez E, Bardales Y, Valeriano-Lorenzo L. Dem\u00eancia Mista: Revis\u00e3o Das evid\u00eancias. Dement E Neuropsychol. 2017;11(4):364\u201370.","journal-title":"Dement E Neuropsychol"},{"key":"1863_CR79","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.2147\/IJN.S200490","volume":"14","author":"S Tiwari","year":"2019","unstructured":"Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M. Alzheimer\u2019s disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomed. 2019;14:5541\u201354.","journal-title":"Int J Nanomed"},{"key":"1863_CR80","doi-asserted-by":"crossref","unstructured":"Ling TS, Chandrasegaran S, Xuan LZ, Suan TL, Elaine E, Nathan DV et al. The Potential Benefits of Nanotechnology in Treating Alzheimer\u2019s Disease. Biomed Res Int. 2021;2021.","DOI":"10.1155\/2021\/5550938"},{"issue":"6","key":"1863_CR81","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1111\/ejn.16229","volume":"59","author":"CG Cooper","year":"2024","unstructured":"Cooper CG, Kafetzis KN, Patabendige A, Tagalakis AD. Blood\u2013brain barrier disruption in dementia: Nano-solutions as new treatment options. Eur J Neurosci. 2024;59(6):1359\u201385.","journal-title":"Eur J Neurosci"},{"key":"1863_CR82","doi-asserted-by":"crossref","unstructured":"Le NTT, Cao V, Du, Nguyen TNQ, Le TTH, Tran TT, Thi TTH. Soy lecithin-derived liposomal delivery systems: surface modification and current applications. Int J Mol Sci. 2019;20(19).","DOI":"10.3390\/ijms20194706"},{"key":"1863_CR83","doi-asserted-by":"publisher","first-page":"8507","DOI":"10.2147\/IJN.S183117","volume":"13","author":"C Ross","year":"2018","unstructured":"Ross C, Taylor M, Fullwood N, Allsop D. Liposome delivery systems for the treatment of Alzheimer\u2019s disease. Int J Nanomed. 2018;13:8507\u201322.","journal-title":"Int J Nanomed"},{"issue":"21","key":"1863_CR84","doi-asserted-by":"publisher","first-page":"8370","DOI":"10.1523\/JNEUROSCI.21-21-08370.2001","volume":"21","author":"GP Lim","year":"2001","unstructured":"Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM. The curry spice Curcumin reduces oxidative damage and amyloid pathology in an alzheimer Transgenic mouse. J Neurosci. 2001;21(21):8370\u20137.","journal-title":"J Neurosci"},{"issue":"5","key":"1863_CR85","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.nano.2011.05.004","volume":"7","author":"F Re","year":"2011","unstructured":"Re F, Cambianica I, Zona C, Sesana S, Gregori M, Rigolio R, et al. Functionalization of liposomes with ApoE-derived peptides at different density affects cellular uptake and drug transport across a blood-brain barrier model. Nanomed Nanatechnol Biol Med. 2011;7(5):551\u20139.","journal-title":"Nanomed Nanatechnol Biol Med"},{"issue":"25","key":"1863_CR86","doi-asserted-by":"publisher","first-page":"6519","DOI":"10.1016\/j.biomaterials.2010.04.044","volume":"31","author":"M Gobbi","year":"2010","unstructured":"Gobbi M, Re F, Canovi M, Beeg M, Gregori M, Sesana S, et al. Lipid-based nanoparticles with high binding affinity for amyloid-\u03b21\u201342 peptide. Biomaterials. 2010;31(25):6519\u201329.","journal-title":"Biomaterials"},{"key":"1863_CR87","doi-asserted-by":"publisher","first-page":"105909","DOI":"10.1016\/j.ejps.2021.105909","volume":"164","author":"PK Srivastava","year":"2021","unstructured":"Srivastava PK, Thakkar HP. European journal of pharmaceutical sciences QbD-driven development of dissolving microneedle patch loaded with ultradeformable liposomes encapsulated noopept: exploring a patient friendly, once-daily option to manage dementia. Eur J Pharm Sci. 2021;164:105909. (December 2020).","journal-title":"Eur J Pharm Sci"},{"key":"1863_CR88","unstructured":"Yung-chih K, Yung-i L, Rajendiran R. Dual functional liposomes carrying antioxidants against Tau hyperphosphorylation and apoptosis of neurons. Journal of Drug Targeting. Volume 0. Taylor & Francis; 2020. p. 000."},{"key":"1863_CR89","doi-asserted-by":"publisher","unstructured":"Shariare MH, Rahman M, Lubna SR, Roy RS, Abedin J, Marzan AL, et al. Liposomal drug delivery of Aphanamixis polystachya leaf extracts and its neurobehavioral activity in mice model. Sci Rep. 2020;10(1):6938. https:\/\/doi.org\/10.1038\/s41598-020-63894-9","DOI":"10.1038\/s41598-020-63894-9"},{"issue":"20","key":"1863_CR90","doi-asserted-by":"publisher","first-page":"e39607","DOI":"10.1016\/j.heliyon.2024.e39607","volume":"10","author":"N Wang","year":"2024","unstructured":"Wang N, Parsons TM, Ren Y, Pan Y, Kurti A, Starling SC, et al. Brain-targeting liposome-based APOE2 gene delivery exacerbates soluble amyloid-\u03b2 accumulation in AppNL\u2013\u2009G-F mice. Heliyon. 2024;10(20):e39607.","journal-title":"Heliyon"},{"issue":"May","key":"1863_CR91","doi-asserted-by":"publisher","first-page":"112233","DOI":"10.1016\/j.msec.2021.112233","volume":"127","author":"YC Kuo","year":"2021","unstructured":"Kuo YC, Ng IW, Rajesh R. Glutathione- and Apolipoprotein E-grafted liposomes to regulate mitogen-activated protein kinases and rescue neurons in Alzheimer\u2019s disease. Mater Sci Eng C. 2021;127(May):112233.","journal-title":"Mater Sci Eng C"},{"issue":"2","key":"1863_CR92","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.etap.2012.04.012","volume":"34","author":"W Li","year":"2012","unstructured":"Li W, Zhou Y, Zhao N, Hao B, Wang X, Kong P. Pharmacokinetic behavior and efficiency of acetylcholinesterase Inhibition in rat brain after intranasal administration of Galanthamine hydrobromide loaded flexible liposomes. Environ Toxicol Pharmacol. 2012;34(2):272\u20139.","journal-title":"Environ Toxicol Pharmacol"},{"issue":"6","key":"1863_CR93","doi-asserted-by":"publisher","first-page":"e09575","DOI":"10.1016\/j.heliyon.2022.e09575","volume":"8","author":"SRK Pandian","year":"2022","unstructured":"Pandian SRK, Vijayakumar KK, Murugesan S, Kunjiappan S. Liposomes: an emerging carrier for targeting Alzheimer\u2019s and Parkinson\u2019s diseases. Heliyon. 2022;8(6):e09575.","journal-title":"Heliyon"},{"key":"1863_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1533317520976761","volume":"35","author":"JS D\u2019Arrigo","year":"2020","unstructured":"D\u2019Arrigo JS. Nanotargeting of Drug(s) for delaying dementia: relevance of Covid-19 impact on dementia. Am J Alzheimers Dis Other Demen. 2020;35:1\u201312.","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"1863_CR95","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jconrel.2017.08.033","volume":"264","author":"C Tapeinos","year":"2017","unstructured":"Tapeinos C, Battaglini M, Ciofani G. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J Control Release. 2017;264:306\u201332.","journal-title":"J Control Release"},{"issue":"1","key":"1863_CR96","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jconrel.2014.04.015","volume":"185","author":"S Moghassemi","year":"2014","unstructured":"Moghassemi S, Hadjizadeh A. Nano-niosomes as nanoscale drug delivery systems: an illustrated review. J Control Release. 2014;185(1):22\u201336.","journal-title":"J Control Release"},{"issue":"3","key":"1863_CR97","doi-asserted-by":"publisher","first-page":"140","DOI":"10.4103\/2230-973X.104397","volume":"2","author":"V Sabale","year":"2012","unstructured":"Sabale V, Vora S. Formulation and evaluation of microemulsion-based hydrogel for topical delivery. Int J Pharm Investig. 2012;2(3):140.","journal-title":"Int J Pharm Investig"},{"key":"1863_CR98","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.progpolymsci.2016.09.006","volume":"64","author":"S Mignani","year":"2017","unstructured":"Mignani S, Bryszewska M, Zablocka M, Klajnert-Maculewicz B, Cladera J, Shcharbin D, et al. Can dendrimer based nanoparticles fight neurodegenerative diseases? Current situation versus other established approaches. Prog Polym Sci. 2017;64:23\u201351.","journal-title":"Prog Polym Sci"},{"issue":"50","key":"1863_CR99","doi-asserted-by":"publisher","first-page":"59673","DOI":"10.1021\/acsami.1c17823","volume":"13","author":"AR Ara\u00fajo","year":"2021","unstructured":"Ara\u00fajo AR, Correa J, Dominguez-Arca V, Reis RL, Fernandez-Megia E, Pires RA. Functional Gallic Acid-Based dendrimers as synthetic nanotools to remodel Amyloid-\u03b2-42 into noncytotoxic forms. ACS Appl Mater Interfaces. 2021;13(50):59673\u201382.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1863_CR100","doi-asserted-by":"crossref","unstructured":"Gharbavi M, Amani J, Kheiri-Manjili H, Danafar H, Sharafi A, Niosome. A Promising Nanocarrier for Natural Drug Delivery through Blood-Brain Barrier. Adv Pharmacol Sci [Internet]. 2018 [cited 2024 Oct 19];2018. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30651728\/","DOI":"10.1155\/2018\/6847971"},{"key":"1863_CR101","doi-asserted-by":"publisher","unstructured":"Ag Seleci D, Seleci M, Walter JG, Stahl F, Scheper T. Niosomes as Nanoparticular Drug Carriers: Fundamentals and Recent Applications. J Nanomater [Internet]. 2016 Jan 1 [cited 2024 Oct 19];2016(1):7372306. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/full\/https:\/\/doi.org\/10.1155\/2016\/7372306","DOI":"10.1155\/2016\/7372306"},{"key":"1863_CR102","doi-asserted-by":"publisher","first-page":"5561","DOI":"10.2147\/IJN.S149022","volume":"13","author":"S Ramanathan","year":"2018","unstructured":"Ramanathan S, Archunan G, Sivakumar M, Selvan ST, Fred AL, Kumar S, et al. Theranostic applications of nanoparticles in neurodegenerative disorders. Int J Nanomed. 2018;13:5561\u201376.","journal-title":"Int J Nanomed"},{"issue":"4","key":"1863_CR103","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3390\/medicines5040126","volume":"5","author":"M Rakotoarisoa","year":"2018","unstructured":"Rakotoarisoa M, Angelova A. Amphiphilic nanocarrier systems for Curcumin delivery in neurodegenerative disorders. Medicines. 2018;5(4):126.","journal-title":"Medicines"},{"key":"1863_CR104","doi-asserted-by":"publisher","unstructured":"Jeon KI, Byun MS, Jue DM. Gold compound auranofin inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKbeta subunit. Exp Mol Med. 2003;35(2):61\u201366. https:\/\/doi.org\/10.1038\/emm.2003.9","DOI":"10.1038\/emm.2003.9"},{"issue":"12","key":"1863_CR105","first-page":"227","volume":"16","author":"GDB Silveira","year":"2023","unstructured":"Silveira GDB, Casagrande LDR, Venturini LM, De Oliveira J, Silveira PCL. The use of gold nanoparticles in the treatment of neurodegenerative diseases. Gold Nanopart Drug Deliv. 2023;16(12):227\u201350.","journal-title":"Gold Nanopart Drug Deliv"},{"key":"1863_CR106","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.msec.2017.03.283","volume":"77","author":"AP Muller","year":"2017","unstructured":"Muller AP, Ferreira GK, Pires AJ, de Bem Silveira G, de Souza DL, de Brandolfi J. Gold nanoparticles prevent cognitive deficits, oxidative stress and inflammation in a rat model of sporadic dementia of Alzheimer\u2019s type. Mater Sci Eng C. 2017;77:476\u201383.","journal-title":"Mater Sci Eng C"},{"issue":"16","key":"1863_CR107","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/smll.201906861","volume":"16","author":"SK Vimal","year":"2020","unstructured":"Vimal SK, Zuo H, Wang Z, Wang H, Long Z, Bhattacharyya S. Self-Therapeutic nanoparticle that alters Tau protein and ameliorates tauopathy toward a functional nanomedicine to tackle Alzheimer\u2019s. Small. 2020;16(16):1\u201311.","journal-title":"Small"},{"key":"1863_CR108","doi-asserted-by":"crossref","unstructured":"Zhou Y, Zhu F, Liu Y, Zheng M, Wang Y, Zhang D et al. Blood-brain barrier\u2013penetrating SiRNA nanomedicine for Alzheimer\u2019s disease therapy. Sci Adv. 2020;6(41).","DOI":"10.1126\/sciadv.abc7031"},{"issue":"8","key":"1863_CR109","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s00210-021-02096-0","volume":"394","author":"SKL Rompicherla","year":"2021","unstructured":"Rompicherla SKL, Arumugam K, Bojja SL, Kumar N, Rao CM. Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based Rivastigmine formulations in acute and chronic models of Alzheimer\u2019s disease. Naunyn Schmiedebergs Arch Pharmacol. 2021;394(8):1737\u201355.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"issue":"March","key":"1863_CR110","doi-asserted-by":"publisher","first-page":"105314","DOI":"10.1016\/j.ejps.2020.105314","volume":"148","author":"RGR Pinheiro","year":"2020","unstructured":"Pinheiro RGR, Granja A, Loureiro JA, Pereira MC, Pinheiro M, Neves AR, et al. Quercetin lipid nanoparticles functionalized with transferrin for Alzheimer\u2019s disease. Eur J Pharm Sci. 2020;148(March):105314.","journal-title":"Eur J Pharm Sci"},{"issue":"September","key":"1863_CR111","doi-asserted-by":"publisher","first-page":"9943","DOI":"10.2147\/IJN.S479242","volume":"19","author":"Y Yang","year":"2024","unstructured":"Yang Y, Wang Y, Jiang X, Mi J, Ge D, Tong Y, et al. Modified Ce\/Zr-MOF nanoparticles loaded with Curcumin for Alzheimer\u2019s disease via multifunctional modulation. Int J Nanomed. 2024;19(September):9943\u201359.","journal-title":"Int J Nanomed"},{"issue":"1","key":"1863_CR112","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-024-58601-x","volume":"14","author":"AB Darwish","year":"2024","unstructured":"Darwish AB, Mohsen AM, Elshebiney S, Elgohary R, Younis MM. Development of Chitosan lipid nanoparticles to alleviate the Pharmacological activity of Piperine in the management of cognitive deficit in diabetic rats. Sci Rep. 2024;14(1):1\u201317.","journal-title":"Sci Rep"},{"issue":"February","key":"1863_CR113","doi-asserted-by":"publisher","first-page":"107082","DOI":"10.1016\/j.nlm.2019.107082","volume":"166","author":"T Dara","year":"2019","unstructured":"Dara T, Vatanara A, Sharifzadeh M, Khani S, Vakilinezhad MA, Vakhshiteh F, et al. Improvement of memory deficits in the rat model of Alzheimer\u2019s disease by erythropoietin-loaded solid lipid nanoparticles. Neurobiol Learn Mem. 2019;166(February):107082.","journal-title":"Neurobiol Learn Mem"},{"issue":"8","key":"1863_CR114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics13081183","volume":"13","author":"MK Satapathy","year":"2021","unstructured":"Satapathy MK, Yen TL, Jan JS, Tang RD, Wang JY, Taliyan R, et al. Solid lipid nanoparticles (Slns): an advanced drug delivery system targeting brain through Bbb. Pharmaceutics. 2021;13(8):1\u201336.","journal-title":"Pharmaceutics"},{"issue":"4","key":"1863_CR115","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.3109\/10717544.2015.1089956","volume":"23","author":"S Misra","year":"2016","unstructured":"Misra S, Chopra K, Sinha VR, Medhi B. Galantamine-loaded solid\u2013lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations. Drug Deliv. 2016;23(4):1434\u201343.","journal-title":"Drug Deliv"},{"issue":"February","key":"1863_CR116","doi-asserted-by":"publisher","first-page":"100029","DOI":"10.1016\/j.crbeha.2021.100029","volume":"2","author":"B Prathipati","year":"2021","unstructured":"Prathipati B, Rohini P, Kola PK, Reddy Danduga RCS. Neuroprotective effects of Curcumin loaded solid lipid nanoparticles on homocysteine induced oxidative stress in vascular dementia. Curr Res Behav Sci. 2021;2(February):100029.","journal-title":"Curr Res Behav Sci"},{"key":"1863_CR117","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.neuint.2017.08.001","volume":"112","author":"A Yadav","year":"2018","unstructured":"Yadav A, Sunkaria A, Singhal N, Sandhir R. Resveratrol loaded solid lipid nanoparticles attenuate mitochondrial oxidative stress in vascular dementia by activating Nrf2\/HO-1 pathway. Neurochem Int. 2018;112:239\u201354.","journal-title":"Neurochem Int"},{"issue":"1","key":"1863_CR118","first-page":"1","volume":"13","author":"GR Topal","year":"2021","unstructured":"Topal GR, M\u00e9sz\u00e1ros M, Porkol\u00e1b G, Szecsk\u00f3 A, Polg\u00e1r TF, Sikl\u00f3s L, et al. ApoE-Targeting increases the transfer of solid lipid nanoparticles with donepezil cargo across a culture model of the Blood\u2013Brain barrier. Pharmaceutics. 2021;13(1):1\u201319.","journal-title":"Pharmaceutics"},{"key":"1863_CR119","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.npep.2016.03.002","volume":"58","author":"A Vedagiri","year":"2016","unstructured":"Vedagiri A, Thangarajan S. Mitigating effect of Chrysin loaded solid lipid nanoparticles against amyloid \u03b225\u201335 induced oxidative stress in rat hippocampal region: an efficient formulation approach for Alzheimer\u2019s disease. Neuropeptides. 2016;58:111\u201325.","journal-title":"Neuropeptides"},{"issue":"1","key":"1863_CR120","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12906-023-04125-2","volume":"23","author":"R Islamie","year":"2023","unstructured":"Islamie R, Myint SLL, Rojanaratha T, Ritthidej G, Wanakhachornkrai O, Wattanathamsan O, et al. Neuroprotective effect of nose-to-brain delivery of Asiatic acid in solid lipid nanoparticles and its mechanisms against memory dysfunction induced by amyloid Beta1-42 in mice. BMC Complement Med Ther. 2023;23(1):1\u201318.","journal-title":"BMC Complement Med Ther"},{"issue":"3","key":"1863_CR121","doi-asserted-by":"publisher","first-page":"446","DOI":"10.34172\/apb.2023.056","volume":"13","author":"S Khan","year":"2023","unstructured":"Khan S, Sharma A, Jain V. An overview of nanostructured lipid carriers and its application in drug delivery through different routes. Adv Pharm Bull. 2023;13(3):446\u201360.","journal-title":"Adv Pharm Bull"},{"issue":"1\u20133","key":"1863_CR122","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.colsurfa.2007.08.005","volume":"315","author":"F Han","year":"2008","unstructured":"Han F, Li S, Yin R, Liu H, Xu L. Effect of surfactants on the formation and characterization of a new type of colloidal drug delivery system: nanostructured lipid carriers. Colloids Surf Physicochem Eng Asp. 2008;315(1\u20133):210\u20136.","journal-title":"Colloids Surf Physicochem Eng Asp"},{"issue":"4","key":"1863_CR123","first-page":"763","volume":"12","author":"AR Tekade","year":"2022","unstructured":"Tekade AR, Mittha PS, Pisal CS. Nanostructured lipid carriers for nose to brain delivery targeting CNS: diversified role of liquid lipids for synergistic action. Adv Pharm Bull. 2022;12(4):763\u201371.","journal-title":"Adv Pharm Bull"},{"issue":"4","key":"1863_CR124","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics14040836","volume":"14","author":"BA Witika","year":"2022","unstructured":"Witika BA, Poka MS, Demana PH, Matafwali SK, Melamane S, Khamanga SMM, et al. Lipid-Based nanocarriers for neurological disorders: A review of the State-of-the-Art and therapeutic success to date. Pharmaceutics. 2022;14(4):1\u201344.","journal-title":"Pharmaceutics"},{"issue":"2","key":"1863_CR125","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1517\/17425240802712590","volume":"6","author":"S Doktorovova","year":"2009","unstructured":"Doktorovova S, Souto EB. Nanostructured lipid carrier-based hydrogel formulations for drug delivery: A comprehensive review. Expert Opin Drug Deliv. 2009;6(2):165\u201376.","journal-title":"Expert Opin Drug Deliv"},{"issue":"November 2018","key":"1863_CR126","doi-asserted-by":"publisher","first-page":"104794","DOI":"10.1016\/j.chemphyslip.2019.104794","volume":"224","author":"MK Chauhan","year":"2019","unstructured":"Chauhan MK, Sharma PK. Optimization and characterization of Rivastigmine nanolipid carrier loaded transdermal patches for the treatment of dementia. Chem Phys Lipids. 2019;224(November 2018):104794.","journal-title":"Chem Phys Lipids"},{"key":"1863_CR127","doi-asserted-by":"crossref","unstructured":"Mohanty D, Alsaidan OA, Zafar A, Dodle T, Gupta JK, Yasir M et al. Development of Atomoxetine-Loaded NLC in situ gel for Nose-to-Brain delivery: optimization, in vitro, and preclinical evaluation. Pharmaceutics. 2023;15(7).","DOI":"10.3390\/pharmaceutics15071985"},{"issue":"5","key":"1863_CR128","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1248\/cpb.58.656","volume":"58","author":"CR Yang","year":"2010","unstructured":"Yang CR, Zhao XL, Hu HY, Li KX, Sun X, Li L, et al. Preparation, optimization and characteristic of huperzine a loaded nanostructured lipid carriers. Chem Pharm Bull. 2010;58(5):656\u201361.","journal-title":"Chem Pharm Bull"},{"key":"1863_CR129","doi-asserted-by":"publisher","unstructured":"Sonawane D, Pokharkar V. Nose to brain targeting of the donepezil nanostructured lipid carrier in situ gel: formulation, in vitro, ex vivo, in vivo pharmacokinetic and pharmacodynamic characterization. RSC Pharm. 2024;820\u201340. https:\/\/doi.org\/10.1039\/D4PM00174E","DOI":"10.1039\/D4PM00174E"},{"issue":"2","key":"1863_CR130","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.ijpharm.2011.12.009","volume":"423","author":"MJ Tsai","year":"2012","unstructured":"Tsai MJ, Wu PC, Huang Y, Bin, Chang JS, Lin CL, Tsai YH, et al. Baicalein loaded in Tocol nanostructured lipid carriers (tocol NLCs) for enhanced stability and brain targeting. Int J Pharm. 2012;423(2):461\u201370.","journal-title":"Int J Pharm"},{"key":"1863_CR131","doi-asserted-by":"publisher","first-page":"102695","DOI":"10.1016\/j.jddst.2021.102695","volume":"66","author":"S Lohan","year":"2021","unstructured":"Lohan S, Sharma T, Saini S, Singh A, Kumar A, Raza K, et al. Galactosylated nanoconstructs of Berberine with enhanced biopharmaceutical and cognitive potential: A preclinical evidence in alzheimer \u2018s disease. J Drug Deliv Sci Technol. 2021;66:102695.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"2","key":"1863_CR132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics13020201","volume":"13","author":"A Froelich","year":"2021","unstructured":"Froelich A, Osma\u0142ek T, Jadach B, Puri V, Michniak-Kohn B. Microemulsion-based media in nose-to-brain drug delivery. Pharmaceutics. 2021;13(2):1\u201337.","journal-title":"Pharmaceutics"},{"key":"1863_CR133","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cocis.2016.02.001","volume":"22","author":"B Kronberg","year":"2016","unstructured":"Kronberg B. The hydrophobic effect. Curr Opin Colloid Interface Sci. 2016;22:14\u201322.","journal-title":"Curr Opin Colloid Interface Sci"},{"issue":"8","key":"1863_CR134","first-page":"990","volume":"80","author":"BK Paul","year":"2001","unstructured":"Paul BK, Moulik SP. Uses and applications of microemulsions. Curr Sci. 2001;80(8):990\u20131001.","journal-title":"Curr Sci"},{"key":"1863_CR135","first-page":"1","volume":"2012","author":"SS Solanki","year":"2012","unstructured":"Solanki SS, Sarkar B, Dhanwani RK. Microemulsion drug delivery system: for bioavailability enhancement of ampelopsin. ISRN Pharm. 2012;2012:1\u20134.","journal-title":"ISRN Pharm"},{"issue":"2","key":"1863_CR136","first-page":"243","volume":"51","author":"RB Patel","year":"2013","unstructured":"Patel RB, Patel MR, Bhatt KK, Patel BG. Formulation consideration and characterization of microemulsion drug delivery system for transnasal administration of carbamazepine. Bull Fac Pharm Cairo Univ. 2013;51(2):243\u201353.","journal-title":"Bull Fac Pharm Cairo Univ"},{"issue":"6","key":"1863_CR137","doi-asserted-by":"publisher","first-page":"854","DOI":"10.3109\/03639045.2015.1066799","volume":"42","author":"A Froelich","year":"2016","unstructured":"Froelich A, Osma\u0142ek T, Kunstman P, Roszak R, Bia\u0142as W. Rheological and textural properties of microemulsion-based polymer gels with indomethacin. Drug Dev Ind Pharm. 2016;42(6):854\u201361.","journal-title":"Drug Dev Ind Pharm"},{"issue":"February","key":"1863_CR138","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.ijpharm.2019.02.011","volume":"560","author":"G Mojeiko","year":"2019","unstructured":"Mojeiko G, de Brito M, Salata GC, Lopes LB. Combination of microneedles and microemulsions to increase celecoxib topical delivery for potential application in chemoprevention of breast cancer. Int J Pharm. 2019;560(February):365\u201376.","journal-title":"Int J Pharm"},{"key":"1863_CR139","doi-asserted-by":"crossref","unstructured":"Patil V, Mhamane S, More S, Pawar A, Arulmozhi S. Exploring the protective effect exhibited by curcumin-loaded coconut oil microemulsion in the experimental models of neurodegeneration: an insight of formulation development, in vitro and in vivo study. Futur J Pharm Sci. 2022;8(1).","DOI":"10.1186\/s43094-022-00441-5"},{"issue":"January","key":"1863_CR140","doi-asserted-by":"publisher","first-page":"101661","DOI":"10.1016\/j.jddst.2020.101661","volume":"57","author":"D Khunt","year":"2020","unstructured":"Khunt D, Polaka S, Shrivas M, Misra M. Biodistribution and amyloid beta induced cell line toxicity study of intranasal Rivastigmine microemulsion enriched with fish oil and butter oil. J Drug Deliv Sci Technol. 2020;57(January):101661.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1863_CR141","doi-asserted-by":"crossref","unstructured":"Ning WJ, Lv RJ, Xu N, Hou XY, Shen C, Guo YL et al. Lycopene-Loaded Microemulsion Regulates Neurogenesis in Rats with A \u03b2-Induced Alzheimer\u2019s Disease Rats Based on the Wnt\/ \u03b2 -catenin Pathway. Neural Plast. 2021;2021.","DOI":"10.1155\/2021\/5519330"},{"issue":"2","key":"1863_CR142","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.apsb.2014.02.002","volume":"4","author":"R Pathak","year":"2014","unstructured":"Pathak R, Prasad Dash R, Misra M, Nivsarkar M. Role of mucoadhesive polymers in enhancing delivery of nimodipine microemulsion to brain via intranasal route. Acta Pharm Sin B. 2014;4(2):151\u201360.","journal-title":"Acta Pharm Sin B"},{"issue":"February","key":"1863_CR143","doi-asserted-by":"publisher","first-page":"117394","DOI":"10.1016\/j.lfs.2020.117394","volume":"245","author":"P Nirale","year":"2020","unstructured":"Nirale P, Paul A, Yadav KS. Nanoemulsions for targeting the neurodegenerative diseases: Alzheimer\u2019s, Parkinson\u2019s and Prion\u2019s. Life Sci. 2020;245(February):117394.","journal-title":"Life Sci"},{"issue":"2","key":"1863_CR144","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics11020084","volume":"11","author":"MC Bonferoni","year":"2019","unstructured":"Bonferoni MC, Rossi S, Sandri G, Ferrari F, Gavini E, Rassu G, et al. Nanoemulsions for nose-to-brain drug delivery. Pharmaceutics. 2019;11(2):1\u201317.","journal-title":"Pharmaceutics"},{"issue":"March","key":"1863_CR145","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.ijpharm.2019.05.032","volume":"565","author":"B Chatterjee","year":"2019","unstructured":"Chatterjee B, Gorain B, Mohananaidu K, Sengupta P, Mandal UK, Choudhury H. Targeted drug delivery to the brain via intranasal nanoemulsion: available proof of concept and existing challenges. Int J Pharm. 2019;565(March):258\u201368.","journal-title":"Int J Pharm"},{"issue":"1","key":"1863_CR146","doi-asserted-by":"publisher","first-page":"113","DOI":"10.36959\/734\/381","volume":"5","author":"SD Joseph","year":"2021","unstructured":"Joseph SD. Drug nanotargeting for treating vascular dementia and Alzheimer\u2019s disease. Alzheimers Dis Dement. 2021;5(1):113\u20138.","journal-title":"Alzheimers Dis Dement"},{"issue":"2","key":"1863_CR147","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2147\/nedt.2007.3.2.245","volume":"3","author":"RR Tampi","year":"2007","unstructured":"Tampi RR, van Dyck CH, Memantine. Efficacy and safety in mild-to-severe Alzheimer\u2019s disease. Neuropsychiatr Dis Treat. 2007;3(2):245\u201358.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"5","key":"1863_CR148","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1080\/02652048.2020.1756971","volume":"37","author":"A Kaur","year":"2020","unstructured":"Kaur A, Nigam K, Srivastava S, Tyagi A, Dang S. Memantine nanoemulsion: a new approach to treat Alzheimer\u2019s disease. J Microencapsul. 2020;37(5):355\u201365.","journal-title":"J Microencapsul"},{"key":"1863_CR149","doi-asserted-by":"publisher","first-page":"e316","DOI":"10.1016\/j.jns.2013.07.1182","volume":"333","author":"S Sood","year":"2013","unstructured":"Sood S, Jain K, Gowthamarajan K. Intranasal delivery of curcumin\u2013\/INS;donepezil nanoemulsion for brain targeting in Alzheimer\u2019s disease. J Neurol Sci. 2013;333:e316\u20137.","journal-title":"J Neurol Sci"},{"key":"1863_CR150","doi-asserted-by":"crossref","unstructured":"Alaqeel NK, Alsheikh MH. Quercetin Nanoemulsion Ameliorates Neuronal Dysfunction in Experimental Alzheimer \u2019 s Disease Model. 2022;1\u201313.","DOI":"10.3390\/antiox11101986"},{"key":"1863_CR151","doi-asserted-by":"crossref","unstructured":"Song Y, Wang X, Wang X, Wang J, Hao Q, Hao J et al. Osthole-Loaded Nanoemulsion Enhances Brain Target in the Treatment of Alzheimer\u2019s Disease via Intranasal Administration. Oxid Med Cell Longev. 2021;2021.","DOI":"10.1155\/2021\/8844455"},{"key":"1863_CR152","doi-asserted-by":"crossref","unstructured":"Chen CY, Tsai TY, Chen BH. Effects of black Garlic extract and nanoemulsion on the deoxy corticosterone acetate-salt induced hypertension and its associated mild cognitive impairment in rats. Antioxidants. 2021;10(10).","DOI":"10.3390\/antiox10101611"},{"key":"1863_CR153","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.ijbiomac.2018.06.190","volume":"118","author":"S Md","year":"2018","unstructured":"Md S, Gan SY, Haw YH, Ho CL, Wong S, Choudhury H. In vitro neuroprotective effects of naringenin nanoemulsion against \u03b2-amyloid toxicity through the regulation of amyloidogenesis and Tau phosphorylation. Int J Biol Macromol. 2018;118:1211\u20139.","journal-title":"Int J Biol Macromol"},{"key":"1863_CR154","doi-asserted-by":"crossref","unstructured":"Khallaf RA, Aboud HM, Sayed OM. Surface modified niosomes of olanzapine for brain targeting via nasal route; preparation, optimization, and in vivo evaluation. J Liposome Res [Internet]. 2020 Apr 2 [cited 2024 Oct 22];30(2):163\u201373. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/31039651\/","DOI":"10.1080\/08982104.2019.1610435"},{"issue":"February","key":"1863_CR155","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpb.2021.02.015","volume":"163","author":"P Kulkarni","year":"2021","unstructured":"Kulkarni P, Rawtani D, Barot T. Design, development and in-vitro\/in-vivo evaluation of intranasally delivered Rivastigmine and N-Acetyl cysteine loaded bifunctional niosomes for applications in combinative treatment of Alzheimer\u2019s disease. Eur J Pharm Biopharm. 2021;163(February):1\u201315.","journal-title":"Eur J Pharm Biopharm"},{"issue":"10","key":"1863_CR156","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1023\/A:1026422915326","volume":"17","author":"C Dufes","year":"2000","unstructured":"Dufes C, Sch\u00e4tzlein AG, Tetley L, Gray AI, Watson DG, Olivier JC, et al. Niosomes and polymeric Chitosan based vesicles bearing transferrin and glucose ligands for drug targeting. Pharm Res. 2000;17(10):1250\u20138.","journal-title":"Pharm Res"},{"key":"1863_CR157","doi-asserted-by":"crossref","unstructured":"Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Pr\u00e9at V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release [Internet]. 2012 Jul 20 [cited 2024 Oct 22];161(2):505\u201322. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/22353619\/","DOI":"10.1016\/j.jconrel.2012.01.043"},{"key":"1863_CR158","doi-asserted-by":"crossref","unstructured":"Seju U, Kumar A, Sawant KK. Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: in vitro and in vivo studies. Acta Biomater [Internet]. 2011 [cited 2024 Oct 22];7(12):4169\u201376. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/21839863\/","DOI":"10.1016\/j.actbio.2011.07.025"},{"key":"1863_CR159","doi-asserted-by":"crossref","unstructured":"Musumeci T, Serapide MF, Pellitteri R, Dalpiaz A, Ferraro L, Dal Magro R et al. Oxcarbazepine free or loaded PLGA nanoparticles as effective intranasal approach to control epileptic seizures in rodents. Eur J Pharm Biopharm [Internet]. 2018 Dec 1 [cited 2024 Oct 22];133:309\u201320. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/30399400\/","DOI":"10.1016\/j.ejpb.2018.11.002"},{"key":"1863_CR160","doi-asserted-by":"crossref","unstructured":"Meng Q, Wang A, Hua H, Jiang Y, Wang Y, Mu H et al. Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer\u2019s disease. Int J Nanomedicine [Internet]. 2018 Feb 1 [cited 2024 Oct 22];13:705\u201318. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/29440896\/","DOI":"10.2147\/IJN.S151474"},{"issue":"5","key":"1863_CR161","doi-asserted-by":"publisher","first-page":"102048","DOI":"10.1016\/j.jsps.2024.102048","volume":"32","author":"F Imam","year":"2024","unstructured":"Imam F, Mukhopadhyay S, Kothiyal P, Alshehri S, Saad Alharbi K, Afzal M, et al. Formulation and characterization of polymeric nanoparticle of Rivastigmine for effective management of Alzheimer\u2019s disease. Saudi Pharm J. 2024;32(5):102048.","journal-title":"Saudi Pharm J"},{"key":"1863_CR162","doi-asserted-by":"publisher","unstructured":"Nozal V, Fern\u00e1ndez-G\u00f3mez P, Garc\u00eda-Rubia A, Mart\u00ednez-Gonz\u00e1lez L, Cuevas EP, Carro E, et al. Designing multitarget ligands for neurodegenerative diseases with improved permeability trough PLGA nanoencapsulation. Biomed Pharmacother. 2024;175. https:\/\/doi.org\/10.1016\/j.biopha.2024.116626","DOI":"10.1016\/j.biopha.2024.116626"},{"issue":"July","key":"1863_CR163","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejps.2014.06.024","volume":"63","author":"S Jose","year":"2014","unstructured":"Jose S, Sowmya S, Cinu TA, Aleykutty NA, Thomas S, Souto EB. Surface modified PLGA nanoparticles for brain targeting of Bacoside-A. Eur J Pharm Sci. 2014;63(July):29\u201335.","journal-title":"Eur J Pharm Sci"},{"issue":"May","key":"1863_CR164","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.msec.2018.05.062","volume":"91","author":"YC Kuo","year":"2018","unstructured":"Kuo YC, Tsai HC. Rosmarinic acid- and curcumin-loaded polyacrylamide-cardiolipin-poly(lactide-co-glycolide) nanoparticles with conjugated 83\u2013\u200914 monoclonal antibody to protect \u03b2-amyloid-insulted neurons. Mater Sci Eng C. 2018;91(May):445\u201357.","journal-title":"Mater Sci Eng C"},{"issue":"1","key":"1863_CR165","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12951-016-0227-4","volume":"15","author":"FU Amin","year":"2017","unstructured":"Amin FU, Shah SA, Badshah H, Khan M, Kim MO. Anthocyanins encapsulated by PLGA@PEG nanoparticles potentially improved its free radical scavenging capabilities via p38\/JNK pathway against A\u03b21-42-induced oxidative stress. J Nanobiotechnol. 2017;15(1):1\u201316.","journal-title":"J Nanobiotechnol"},{"key":"1863_CR166","doi-asserted-by":"crossref","unstructured":"Nance E, Zhang F, Mishra MK, Zhang Z, Kambhampati SP, Kannan RM et al. Nanoscale effects in dendrimer-mediated targeting of neuroinflammation. Biomaterials [Internet]. 2016 Sep 1 [cited 2024 Oct 22];101:96\u2013107. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/27267631\/","DOI":"10.1016\/j.biomaterials.2016.05.044"},{"key":"1863_CR167","doi-asserted-by":"crossref","unstructured":"Zhang F, Trent Magruder J, Lin YA, Crawford TC, Grimm JC, Sciortino CM et al. Generation-6 hydroxyl PAMAM dendrimers improve CNS penetration from intravenous administration in a large animal brain injury model. J Control Release [Internet]. 2017 Mar 10 [cited 2024 Oct 22];249:173. Available from: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC5323327\/","DOI":"10.1016\/j.jconrel.2017.01.032"},{"key":"1863_CR168","doi-asserted-by":"crossref","unstructured":"Serram\u00eda MJ, \u00c1lvarez S, Fuentes-Paniagua E, Clemente MI, S\u00e1nchez-Nieves J, G\u00f3mez R et al. In vivo delivery of siRNA to the brain by carbosilane dendrimer. J Control Release [Internet]. 2015 Feb 28 [cited 2024 Oct 22];200:60\u201370. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/25559178\/","DOI":"10.1016\/j.jconrel.2014.12.042"},{"issue":"10","key":"1863_CR169","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1021\/acs.molpharmaceut.8b00537","volume":"15","author":"A Gothwal","year":"2018","unstructured":"Gothwal A, Nakhate KT, Alexander A, Ajazuddin A, Gupta U. Boosted memory and improved brain bioavailability of Rivastigmine: targeting effort to the brain using covalently tethered lower generation PAMAM dendrimers with lactoferrin. Mol Pharm. 2018;15(10):4538\u201349.","journal-title":"Mol Pharm"},{"issue":"1","key":"1863_CR170","first-page":"1","volume":"16","author":"CM Henningfield","year":"2024","unstructured":"Henningfield CM, Soni N, Lee RW, Sharma R, Cleland JL, Green KN. Selective targeting and modulation of plaque associated microglia via systemic hydroxyl dendrimer administration in an Alzheimer\u2019s disease mouse model. Alzheimer\u2019s Res Ther. 2024;16(1):1\u201314.","journal-title":"Alzheimer\u2019s Res Ther"},{"issue":"2","key":"1863_CR171","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1208\/s12248-012-9339-4","volume":"14","author":"N Desai","year":"2012","unstructured":"Desai N. Challenges in development of nanoparticle-based therapeutics. AAPS J. 2012;14(2):282\u201395.","journal-title":"AAPS J"},{"key":"1863_CR172","doi-asserted-by":"crossref","unstructured":"Sharma S, Parveen R, Chatterji BP. Toxicology of Nanoparticles in Drug Delivery. Curr Pathobiol Rep [Internet]. 2021 Dec 1 [cited 2025 Mar 21];9(4):133\u201344. Available from: https:\/\/link.springer.com\/article\/10.1007\/s40139-021-00227-z","DOI":"10.1007\/s40139-021-00227-z"},{"key":"1863_CR173","doi-asserted-by":"publisher","unstructured":"Li X, Wang L, Fan Y, Feng Q, Cui FZ. Biocompatibility and Toxicity of Nanoparticles and Nanotubes. J Nanomater [Internet]. 2012 Jan 1 [cited 2025 Mar 21];2012(1):548389. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/full\/https:\/\/doi.org\/10.1155\/2012\/548389","DOI":"10.1155\/2012\/548389"},{"key":"1863_CR174","doi-asserted-by":"publisher","unstructured":"Pandey G, Jain P. Assessing the nanotechnology on the grounds of costs, benefits, and risks. Beni-Suef Univ J Basic Appl Sci 2020 91 [Internet]. 2020 Dec 10 [cited 2025 Mar 21];9(1):1\u201310. Available from: https:\/\/bjbas.springeropen.com\/articles\/https:\/\/doi.org\/10.1186\/s43088-020-00085-5","DOI":"10.1186\/s43088-020-00085-5"},{"key":"1863_CR175","doi-asserted-by":"publisher","first-page":"104885","DOI":"10.1016\/j.yrtph.2021.104885","volume":"122","author":"J Allan","year":"2021","unstructured":"Allan J, Belz S, Hoeveler A, Hugas M, Okuda H, Patri A, et al. Regulatory landscape of nanotechnology and nanoplastics from a global perspective. Regul Toxicol Pharmacol. 2021;122:104885.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"2","key":"1863_CR176","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1124\/pr.54.2.161","volume":"54","author":"AC Howlett","year":"2002","unstructured":"Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al. International union of pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev. 2002;54(2):161\u2013202.","journal-title":"Pharmacol Rev"},{"issue":"168","key":"1863_CR177","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/3-540-26573-2_11","volume":"168","author":"B Szabo","year":"2005","unstructured":"Szabo B, Schlicker E. Effects of cannabinoids on neurotransmission. Handb Exp Pharmacol. 2005;168(168):327\u201365.","journal-title":"Handb Exp Pharmacol"},{"issue":"10","key":"1863_CR178","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1517\/13543784.11.10.1365","volume":"11","author":"RI Grundy","year":"2002","unstructured":"Grundy RI. The therapeutic potential of the cannabinoids in neuroprotection. Expert Opin Investig Drugs. 2002;11(10):1365\u201374.","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"1863_CR179","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1124\/pr.110.003004","volume":"62","author":"RG Pertwee","year":"2010","unstructured":"Pertwee RG, Howlett AC, Abood ME, Alexander SPH, Di Marzo V, Elphick MR, et al. International union of basic and clinical pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB\u2081 and CB\u2082. Pharmacol Rev. 2010;62(4):588\u2013631.","journal-title":"Pharmacol Rev"},{"issue":"2","key":"1863_CR180","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/FBP.0000000000000247","volume":"28","author":"T Karl","year":"2017","unstructured":"Karl T, Garner B, Cheng D. The therapeutic potential of the phytocannabinoid Cannabidiol for Alzheimer\u2019s disease. Behav Pharmacol. 2017;28(2):142\u201360.","journal-title":"Behav Pharmacol"},{"issue":"1","key":"1863_CR181","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0885-3924(97)00038-9","volume":"14","author":"JE Beal","year":"1997","unstructured":"Beal JE, Olson R, Lefkowitz L, Laubenstein L, Bellman P, Yangco B, et al. Long-term efficacy and safety of dronabinol for acquired immunodeficiency syndrome-associated anorexia. J Pain Symptom Manage. 1997;14(1):7\u201314.","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"1863_CR182","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0091-3057(02)00816-X","volume":"73","author":"RI Block","year":"2002","unstructured":"Block RI, Erwin WJ, Ghoneim MM. Chronic drug use and cognitive impairments. Pharmacol Biochem Behav. 2002;73(3):491\u2013504.","journal-title":"Pharmacol Biochem Behav"},{"issue":"3","key":"1863_CR183","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.neubiorev.2010.04.008","volume":"35","author":"MJ Fern\u00e1ndez-Serrano","year":"2011","unstructured":"Fern\u00e1ndez-Serrano MJ, P\u00e9rez-Garc\u00eda M, Verdejo-Garc\u00eda A. What are the specific vs. generalized effects of drugs of abuse on neuropsychological performance? Neurosci Biobehav Rev. 2011;35(3):377\u2013406.","journal-title":"Neurosci Biobehav Rev"},{"issue":"6","key":"1863_CR184","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1124\/mol.111.071290","volume":"79","author":"AM Mart\u00edn-Moreno","year":"2011","unstructured":"Mart\u00edn-Moreno AM, Reigada D, Ram\u00edrez BG, Mechoulam R, Innamorato N, Cuadrado A, et al. Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer\u2019s disease. Mol Pharmacol. 2011;79(6):964\u201373.","journal-title":"Mol Pharmacol"},{"issue":"3","key":"1863_CR185","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00109-005-0025-1","volume":"84","author":"G Esposito","year":"2006","unstructured":"Esposito G, De Filippis D, Carnuccio R, Izzo AA, Iuvone T. The marijuana component Cannabidiol inhibits beta-amyloid-induced Tau protein hyperphosphorylation through Wnt\/beta-catenin pathway rescue in PC12 cells. J Mol Med (Berl). 2006;84(3):253\u20138.","journal-title":"J Mol Med (Berl)"},{"issue":"4","key":"1863_CR186","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1007\/s00213-006-0343-1","volume":"185","author":"S Walther","year":"2006","unstructured":"Walther S, Mahlberg R, Eichmann U, Kunz D. Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology. 2006;185(4):524\u20138.","journal-title":"Psychopharmacology"},{"key":"1863_CR187","doi-asserted-by":"crossref","unstructured":"Pautex S, Bianchi F, Daali Y, Augsburger M, de Saussure C, Wampfler J et al. Cannabinoids for behavioral symptoms in severe dementia: safety and feasibility in a long-term pilot observational study in nineteen patients. Front Aging Neurosci. 2022;14.","DOI":"10.3389\/fnagi.2022.957665"},{"issue":"2","key":"1863_CR188","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.mehy.2005.08.026","volume":"66","author":"E Russo","year":"2006","unstructured":"Russo E, Guy GW. A Tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and Cannabidiol. Med Hypotheses. 2006;66(2):234\u201346.","journal-title":"Med Hypotheses"},{"key":"1863_CR189","doi-asserted-by":"crossref","unstructured":"Cassano T, Villani R, Pace L, Carbone A, Bukke VN, Orkisz S et al. From Cannabis sativa to Cannabidiol: promising therapeutic candidate for the treatment of neurodegenerative diseases. Front Pharmacol. 2020;11.","DOI":"10.3389\/fphar.2020.00124"},{"key":"1863_CR190","unstructured":"(PDF). Effects of Dronabinol on anorexia and disturbed behavior in patients with Alzheimer\u2019s disease."},{"issue":"1","key":"1863_CR191","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3233\/JAD-150915","volume":"51","author":"A Shelef","year":"2016","unstructured":"Shelef A, Barak Y, Berger U, Paleacu D, Tadger S, Plopsky I, et al. Safety and efficacy of medical Cannabis oil for behavioral and psychological symptoms of dementia: An-Open label, Add-On, pilot study. J Alzheimers Dis. 2016;51(1):15\u20139.","journal-title":"J Alzheimers Dis"},{"key":"1863_CR192","doi-asserted-by":"publisher","unstructured":"Sood A, Mehrotra A, Dhawan DK, Sandhir R. Neuroprotective effects of Withania somnifera on ischemic stroke are mediated via anti-inflammatory response and modulation of neurotransmitter levels. Neurochem Int. 2024;180:105867. https:\/\/doi.org\/10.1016\/j.neuint.2024.105867","DOI":"10.1016\/j.neuint.2024.105867"},{"issue":"14","key":"1863_CR193","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1097\/00001756-200210070-00005","volume":"13","author":"T Kuboyama","year":"2002","unstructured":"Kuboyama T, Tohda C, Zhao J, Nakamura N, Hattori M, Komatsu K. Axon- or dendrite-predominant outgrowth induced by constituents from Ashwagandha. NeuroReport. 2002;13(14):1715\u201320.","journal-title":"NeuroReport"},{"issue":"9","key":"1863_CR194","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1097\/00001756-200006260-00035","volume":"11","author":"C Tohda","year":"2000","unstructured":"Tohda C, Kuboyama T, Komatsu K. Dendrite extension by methanol extract of Ashwagandha (roots of Withania somnifera) in SK-N-SH cells. NeuroReport. 2000;11(9):1981\u20135.","journal-title":"NeuroReport"},{"issue":"6","key":"1863_CR195","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1111\/j.1460-9568.2006.04664.x","volume":"23","author":"T Kuboyama","year":"2006","unstructured":"Kuboyama T, Tohda C, Komatsu K. Withanoside IV and its active metabolite, sominone, attenuate Abeta(25\u201335)-induced neurodegeneration. Eur J Neurosci. 2006;23(6):1417\u201326.","journal-title":"Eur J Neurosci"},{"issue":"11","key":"1863_CR196","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.4088\/JCP.13m08413","volume":"74","author":"KNR Chengappa","year":"2013","unstructured":"Chengappa KNR, Bowie CR, Schlicht PJ, Fleet D, Brar JS, Jindal R. Randomized placebo-controlled adjunctive study of an extract of withania somnifera for cognitive dysfunction in bipolar disorder. J Clin Psychiatry. 2013;74(11):1076\u201383.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"1863_CR197","doi-asserted-by":"publisher","first-page":"12","DOI":"10.4103\/0974-8490.122912","volume":"6","author":"U Pingali","year":"2014","unstructured":"Pingali U, Pilli R, Fatima N. Effect of standardized aqueous extract of Withania somnifera on tests of cognitive and psychomotor performance in healthy human participants. Pharmacognosy Res. 2014;6(1):12\u20138.","journal-title":"Pharmacognosy Res"},{"issue":"April","key":"1863_CR198","first-page":"1","volume":"8","author":"SZ Moradi","year":"2020","unstructured":"Moradi SZ, Momtaz S, Bayrami Z, Farzaei MH, Abdollahi M. Nanoformulations of herbal extracts in treatment of neurodegenerative disorders. Front Bioeng Biotechnol. 2020;8(April):1\u201320.","journal-title":"Front Bioeng Biotechnol"},{"issue":"October","key":"1863_CR199","first-page":"1","volume":"17","author":"N Liu","year":"2023","unstructured":"Liu N, Ruan J, Li H, Fu J. Nanoparticles loaded with natural medicines for the treatment of Alzheimer\u2019s disease. Front Neurosci. 2023;17(October):1\u20139.","journal-title":"Front Neurosci"},{"key":"1863_CR200","doi-asserted-by":"publisher","unstructured":"Mir Najib Ullah SN, Afzal O, Altamimi ASA, Ather H, Sultana S, et al. Nanomedicine in the management of Alzheimer's disease: state-of-the-Art. Biomedicines. 2023;11(6):1752. https:\/\/doi.org\/10.3390\/biomedicines11061752","DOI":"10.3390\/biomedicines11061752"},{"issue":"1","key":"1863_CR201","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2174\/138161212798919075","volume":"18","author":"F Li","year":"2012","unstructured":"Li F, Gong Q, Dong H, Shi J. Resveratrol, a neuroprotective supplement for Alzheimer\u2019s disease. Curr Pharm Des. 2012;18(1):27\u201333.","journal-title":"Curr Pharm Des"},{"key":"1863_CR202","doi-asserted-by":"crossref","unstructured":"Dal-Pan A, Pifferi F, Marchal J, Picq JL, Aujard F. Cognitive performances are selectively enhanced during chronic caloric restriction or Resveratrol supplementation in a primate. PLoS ONE. 2011;6(1).","DOI":"10.1371\/journal.pone.0016581"},{"issue":"5","key":"1863_CR203","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.2337\/db11-1187","volume":"61","author":"AA Willette","year":"2012","unstructured":"Willette AA, Bendlin BB, Colman RJ, Kastman EK, Field AS, Alexander AL, et al. Calorie restriction reduces the influence of glucoregulatory dysfunction on regional brain volume in aged rhesus monkeys. Diabetes. 2012;61(5):1036\u201342.","journal-title":"Diabetes"},{"issue":"2","key":"1863_CR204","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.jpba.2009.03.026","volume":"51","author":"ME Juan","year":"2010","unstructured":"Juan ME, Maij\u00f3 M, Planas JM. Quantification of trans-resveratrol and its metabolites in rat plasma and tissues by HPLC. J Pharm Biomed Anal. 2010;51(2):391\u20138.","journal-title":"J Pharm Biomed Anal"},{"issue":"50","key":"1863_CR205","doi-asserted-by":"publisher","first-page":"7893","DOI":"10.1021\/bi500910b","volume":"53","author":"Z Fu","year":"2014","unstructured":"Fu Z, Aucoin D, Ahmed M, Ziliox M, Van Nostrand WE, Smith SO. Capping of A\u03b242 oligomers by small molecule inhibitors. Biochemistry. 2014;53(50):7893\u2013903.","journal-title":"Biochemistry"},{"issue":"6","key":"1863_CR206","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/bip.22572","volume":"102","author":"M Ghobeh","year":"2014","unstructured":"Ghobeh M, Ahmadian S, Meratan AA, Ebrahim-Habibi A, Ghasemi A, Shafizadeh M, et al. Interaction of A\u03b2(25\u201335) fibrillation products with mitochondria: effect of small-molecule natural products. Biopolymers. 2014;102(6):473\u201386.","journal-title":"Biopolymers"},{"issue":"2","key":"1863_CR207","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.neuint.2008.10.008","volume":"54","author":"SS Karuppagounder","year":"2009","unstructured":"Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE. Dietary supplementation with Resveratrol reduces plaque pathology in a Transgenic model of Alzheimer\u2019s disease. Neurochem Int. 2009;54(2):111\u20138.","journal-title":"Neurochem Int"},{"key":"1863_CR208","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.neuroscience.2015.05.062","volume":"301","author":"P Moorthi","year":"2015","unstructured":"Moorthi P, Premkumar P, Priyanka R, Jayachandran KS, Anusuyadevi M. Pathological changes in hippocampal neuronal circuits underlie age-associated neurodegeneration and memory loss: positive clue toward SAD. Neuroscience. 2015;301:90\u2013105.","journal-title":"Neuroscience"},{"issue":"3","key":"1863_CR209","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1093\/jn\/138.3.519","volume":"138","author":"MF Ritz","year":"2008","unstructured":"Ritz MF, Ratajczak P, Curin Y, Cam E, Mendelowitsch A, Pinet F, et al. Chronic treatment with red wine polyphenol compounds mediates neuroprotection in a rat model of ischemic cerebral stroke. J Nutr. 2008;138(3):519\u201325.","journal-title":"J Nutr"},{"issue":"9","key":"1863_CR210","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1097\/HJH.0b013e328362b9d6","volume":"31","author":"RHX Wong","year":"2013","unstructured":"Wong RHX, Berry NM, Coates AM, Buckley JD, Bryan J, Kunz I, et al. Chronic Resveratrol consumption improves brachial flow-mediated dilatation in healthy obese adults. J Hypertens. 2013;31(9):1819\u201327.","journal-title":"J Hypertens"},{"issue":"6","key":"1863_CR211","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1166\/jbn.2010.1161","volume":"6","author":"RL Frozza","year":"2010","unstructured":"Frozza RL, Bernardi A, Paese K, Hoppe JB, Da Silva T, Battastini AMO, et al. Characterization of trans-resveratrol-loaded lipid-core nanocapsules and tissue distribution studies in rats. J Biomed Nanotechnol. 2010;6(6):694\u2013703.","journal-title":"J Biomed Nanotechnol"},{"issue":"6","key":"1863_CR212","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/sj.bjp.0705688","volume":"141","author":"YS Han","year":"2004","unstructured":"Han YS, Zheng WH, Bastianetto S, Chabot JG, Quirion R. Neuroprotective effects of Resveratrol against beta-amyloid-induced neurotoxicity in rat hippocampal neurons: involvement of protein kinase C. Br J Pharmacol. 2004;141(6):997\u20131005.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"1863_CR213","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/sj.mp.4001204","volume":"8","author":"M Racchi","year":"2003","unstructured":"Racchi M, Mazzucchelli M, Pascale A, Sironi M, Govoni S. Role of protein kinase Calpha in the regulated secretion of the amyloid precursor protein. Mol Psychiatry. 2003;8(2):209\u201316.","journal-title":"Mol Psychiatry"},{"issue":"6","key":"1863_CR214","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.3945\/ajcn.2009.28641","volume":"91","author":"DO Kennedy","year":"2010","unstructured":"Kennedy DO, Wightman EL, Reay JL, Lietz G, Okello EJ, Wilde A, et al. Effects of Resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am J Clin Nutr. 2010;91(6):1590\u20137.","journal-title":"Am J Clin Nutr"},{"issue":"2","key":"1863_CR215","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/jnr.23322","volume":"92","author":"P Wang","year":"2014","unstructured":"Wang P, Su C, Li R, Wang H, Ren Y, Sun H, et al. Mechanisms and effects of Curcumin on Spatial learning and memory improvement in APPswe\/PS1dE9 mice. J Neurosci Res. 2014;92(2):218\u201331.","journal-title":"J Neurosci Res"},{"key":"1863_CR216","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.neulet.2015.03.045","volume":"594","author":"X Shi","year":"2015","unstructured":"Shi X, Zheng Z, Li J, Xiao Z, Qi W, Zhang A, et al. Curcumin inhibits A\u03b2-induced microglial inflammatory responses in vitro: involvement of ERK1\/2 and p38 signaling pathways. Neurosci Lett. 2015;594:105\u201310.","journal-title":"Neurosci Lett"},{"issue":"6","key":"1863_CR217","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/S0197-4580(01)00300-1","volume":"22","author":"SA Frautschy","year":"2001","unstructured":"Frautschy SA, Hu W, Kim P, Miller SA, Chu T, Harris-White ME, et al. Phenolic anti-inflammatory antioxidant reversal of A\u03b2-induced cognitive deficits and neuropathology. Neurobiol Aging. 2001;22(6):993\u20131005.","journal-title":"Neurobiol Aging"},{"issue":"28","key":"1863_CR218","doi-asserted-by":"publisher","first-page":"9078","DOI":"10.1523\/JNEUROSCI.1071-09.2009","volume":"29","author":"QL Ma","year":"2009","unstructured":"Ma QL, Yang F, Rosario ER, Ubeda OJ, Beech W, Gant DJ, et al. \u03b2-Amyloid oligomers induce phosphorylation of Tau and inactivation of insulin receptor substrate via c-Jun N-Terminal kinase signaling: suppression by Omega-3 fatty acids and Curcumin. J Neurosci. 2009;29(28):9078.","journal-title":"J Neurosci"},{"issue":"7","key":"1863_CR219","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1007\/s11064-012-0754-9","volume":"37","author":"HC Huang","year":"2012","unstructured":"Huang HC, Chang P, Dai XL, Jiang ZF. Protective effects of Curcumin on amyloid-\u03b2-induced neuronal oxidative damage. Neurochem Res. 2012;37(7):1584\u201397.","journal-title":"Neurochem Res"},{"issue":"1","key":"1863_CR220","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.jep.2009.08.009","volume":"126","author":"J Tang","year":"2009","unstructured":"Tang J, Feng Y, Tsao S, Wang N, Curtain R, Wang Y. Berberine and coptidis rhizoma as novel antineoplastic agents: A review of traditional use and biomedical investigations. J Ethnopharmacol. 2009;126(1):5\u201317.","journal-title":"J Ethnopharmacol"},{"key":"1863_CR221","doi-asserted-by":"crossref","unstructured":"Han J, Lin H, Huang W. Modulating gut microbiota as an anti-diabetic mechanism of Berberine. Med Sci Monit. 2011;17(7).","DOI":"10.12659\/MSM.881842"},{"issue":"1","key":"1863_CR222","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jep.2009.02.038","volume":"123","author":"J Singh","year":"2009","unstructured":"Singh J, Kakkar P. Antihyperglycemic and antioxidant effect of Berberis aristata root extract and its role in regulating carbohydrate metabolism in diabetic rats. J Ethnopharmacol. 2009;123(1):22\u20136.","journal-title":"J Ethnopharmacol"},{"key":"1863_CR223","doi-asserted-by":"publisher","unstructured":"Zhang N, Gao Y, Yu S, Sun X, Shen K. Berberine attenuates A\u03b242-induced neuronal damage through regulating circHDAC9\/miR-142-5p axis in human neuronal cells. Life sciences. 2020;252:117637. https:\/\/doi.org\/10.1016\/j.lfs.2020.117637","DOI":"10.1016\/j.lfs.2020.117637"},{"issue":"3","key":"1863_CR224","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3233\/JAD-2011-101779","volume":"24","author":"G Yu","year":"2011","unstructured":"Yu G, Tian Q, Liu R, Wang Q, Wang JZ, Wang X. Berberine attenuates Calyculin A-induced cytotoxicity and Tau hyperphosphorylation in HEK293 cells. J Alzheimers Dis. 2011;24(3):525\u201335.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"1863_CR225","first-page":"1197","volume":"8","author":"Q Zhang","year":"2016","unstructured":"Zhang Q, Bian H, Guo L, Zhu H. Pharmacologic preconditioning with Berberine attenuating ischemia-induced apoptosis and promoting autophagy in neuron. Am J Transl Res. 2016;8(2):1197.","journal-title":"Am J Transl Res"},{"issue":"3","key":"1863_CR226","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.taap.2013.08.008","volume":"272","author":"YY Hsu","year":"2013","unstructured":"Hsu YY, Tseng YT, Lo YC. Berberine, a natural antidiabetes drug, attenuates glucose neurotoxicity and promotes Nrf2-related neurite outgrowth. Toxicol Appl Pharmacol. 2013;272(3):787\u201396.","journal-title":"Toxicol Appl Pharmacol"},{"key":"1863_CR227","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.pbb.2013.12.006","volume":"117","author":"PY Zhan","year":"2014","unstructured":"Zhan PY, Peng CX, Zhang LH. Berberine rescues D-galactose-induced synaptic\/memory impairment by regulating the levels of Arc. Pharmacol Biochem Behav. 2014;117:47\u201351.","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"1863_CR228","doi-asserted-by":"publisher","first-page":"79","DOI":"10.4196\/kjpp.2012.16.2.79","volume":"16","author":"B Lee","year":"2012","unstructured":"Lee B, Sur B, Shim I, Lee H, Hahm DH. Phellodendron amurense and its major alkaloid compound, Berberine ameliorates Scopolamine-Induced neuronal impairment and memory dysfunction in rats. Korean J Physiol Pharmacol. 2012;16(2):79\u201389.","journal-title":"Korean J Physiol Pharmacol"},{"issue":"1","key":"1863_CR229","doi-asserted-by":"publisher","first-page":"6075679","DOI":"10.1155\/2016\/6075679","volume":"2016","author":"MKA Sahak","year":"2016","unstructured":"Sahak MKA, Kabir N, Abbas G, Draman S, Hashim NH, Hasan Adli DS. The role of Nigella sativa and its active constituents in learning and memory. Evidence-Based Complement Altern Med. 2016;2016(1):6075679.","journal-title":"Evidence-Based Complement Altern Med"},{"issue":"5","key":"1863_CR230","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S0731-7085(98)00300-8","volume":"19","author":"OA Ghosheh","year":"1999","unstructured":"Ghosheh OA, Houdi AA, Crooks PA. High performance liquid chromatographic analysis of the Pharmacologically active Quinones and related compounds in the oil of the black seed (Nigella sativa L). J Pharm Biomed Anal. 1999;19(5):757\u201362.","journal-title":"J Pharm Biomed Anal"},{"issue":"3","key":"1863_CR231","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s11064-007-9481-z","volume":"33","author":"M Kanter","year":"2008","unstructured":"Kanter M. Nigella sativa and derived thymoquinone prevents hippocampal neurodegeneration after chronic toluene exposure in rats. Neurochem Res. 2008;33(3):579\u201388.","journal-title":"Neurochem Res"},{"issue":"1","key":"1863_CR232","first-page":"5","volume":"5","author":"S Moghaddasi","year":"2011","unstructured":"Moghaddasi S. Nigella Sativa Treditional usages (Black Seed). Adv Environ Biol. 2011;5(1):5\u201316.","journal-title":"Adv Environ Biol"},{"issue":"15","key":"1863_CR233","first-page":"3359","volume":"5","author":"I Norsharina","year":"2011","unstructured":"Norsharina I, Maznah I, Aied AA, Ghanya AN. Thymoquinone rich fraction from Nigella sativa and thymoquinone are cytotoxic towards colon and leukemic carcinoma cell lines. J Med Plants Res. 2011;5(15):3359\u201366.","journal-title":"J Med Plants Res"},{"issue":"3","key":"1863_CR234","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.jep.2013.05.004","volume":"148","author":"MS Bin Sayeed","year":"2013","unstructured":"Bin Sayeed MS, Asaduzzaman M, Morshed H, Hossain MM, Kadir MF, Rahman MR. The effect of Nigella sativa Linn. Seed on memory, attention and cognition in healthy human volunteers. J Ethnopharmacol. 2013;148(3):780\u20136.","journal-title":"J Ethnopharmacol"},{"issue":"6","key":"1863_CR235","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1007\/s11655-014-1742-5","volume":"21","author":"M Hosseini","year":"2015","unstructured":"Hosseini M, Mohammadpour T, Karami R, Rajaei Z, Reza Sadeghnia H, Soukhtanloo M. Effects of the hydro-alcoholic extract of Nigella sativa on scopolamine-induced Spatial memory impairment in rats and its possible mechanism. Chin J Integr Med. 2015;21(6):438\u201344.","journal-title":"Chin J Integr Med"},{"key":"1863_CR236","doi-asserted-by":"crossref","unstructured":"El-Naggar T, G\u00f3mez-Serranillos MP, Palomino OM, Arce C, Carretero ME. Nigella sativa L. seed extract modulates the neurotransmitter amino acids release in cultured neurons in vitro. J Biomed Biotechnol. 2010;2010.","DOI":"10.1155\/2010\/398312"},{"issue":"4","key":"1863_CR237","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.bbrc.2012.11.139","volume":"433","author":"AH Alhebshi","year":"2013","unstructured":"Alhebshi AH, Gotoh M, Suzuki I. Thymoquinone protects cultured rat primary neurons against amyloid \u03b2-induced neurotoxicity. Biochem Biophys Res Commun. 2013;433(4):362\u20137.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"1863_CR238","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10735-009-9220-7","volume":"40","author":"M Kanter","year":"2009","unstructured":"Kanter M. Protective effects of thymoquinone on streptozotocin-induced diabetic nephropathy. J Mol Histol. 2009;40(2):107\u201315.","journal-title":"J Mol Histol"},{"issue":"11","key":"1863_CR239","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1007\/s11064-011-0544-9","volume":"36","author":"HS Aboul Ezz","year":"2011","unstructured":"Aboul Ezz HS, Khadrawy YA, Noor NA. The neuroprotective effect of Curcumin and Nigella sativa oil against oxidative stress in the pilocarpine model of epilepsy: a comparison with valproate. Neurochem Res. 2011;36(11):2195\u2013204.","journal-title":"Neurochem Res"},{"issue":"1","key":"1863_CR240","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1179\/1476830514Y.0000000144","volume":"20","author":"F Beheshti","year":"2017","unstructured":"Beheshti F, Hosseini M, Shafei MN, Soukhtanloo M, Ghasemi S, Vafaee F, et al. The effects of Nigella sativa extract on hypothyroidism-associated learning and memory impairment during neonatal and juvenile growth in rats. Nutr Neurosci. 2017;20(1):49\u201359.","journal-title":"Nutr Neurosci"},{"issue":"1","key":"1863_CR241","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jep.2013.12.050","volume":"152","author":"MS Bin Sayeed","year":"2014","unstructured":"Bin Sayeed MS, Shams T, Fahim Hossain S, Rahman MR, Mostofa A, Fahim Kadir M, et al. Nigella sativa L. seeds modulate mood, anxiety and cognition in healthy adolescent males. J Ethnopharmacol. 2014;152(1):156\u201362.","journal-title":"J Ethnopharmacol"},{"key":"1863_CR242","first-page":"1","volume":"11","author":"N Alzobaidi","year":"2021","unstructured":"Alzobaidi N, Quasimi H, Emad NA, Alhalmi A, Naqvi M. Bioactive compounds and traditional herbal medicine: promising approaches for the treatment of dementia. Degener Neurol Neuromuscul Dis. 2021;11:1.","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"1","key":"1863_CR243","first-page":"124","volume":"6","author":"F Beheshti","year":"2016","unstructured":"Beheshti F, Khazaei M, Hosseini M. Neuropharmacological effects of Nigella sativa. Avicenna J Phytomedicine. 2016;6(1):124\u201341.","journal-title":"Avicenna J Phytomedicine"},{"issue":"9","key":"1863_CR244","first-page":"804","volume":"7","author":"P Sati","year":"2013","unstructured":"Sati P, Pandey A, Rawat S, Rani A. Phytochemicals and antioxidants in leaf extracts of Ginkgo biloba with reference to location, seasonal variation and solvent system. J Pharm Res. 2013;7(9):804\u20139.","journal-title":"J Pharm Res"},{"key":"1863_CR245","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.neuint.2015.08.002","volume":"89","author":"C Rendeiro","year":"2015","unstructured":"Rendeiro C, Rhodes JS, Spencer JPE. The mechanisms of action of flavonoids in the brain: direct versus indirect effects. Neurochem Int. 2015;89:126\u201339.","journal-title":"Neurochem Int"},{"key":"1863_CR246","unstructured":"Chemistry. and Medicinal properties of Tinospora cordifolia (Guduchi)."},{"key":"1863_CR247","doi-asserted-by":"crossref","unstructured":"Rawal AK, Muddeshwar MG, Biswas SK. Rubia cordifolia, Fagonia cretica Linn and Tinospora cordifolia exert neuroprotection by modulating the antioxidant system in rat hippocampal slices subjected to oxygen glucose deprivation. BMC Complement Altern Med. 2004;4.","DOI":"10.1186\/1472-6882-4-11"},{"key":"1863_CR248","unstructured":"(PDF). Effect of Tinospora cordifolia on Learning and Memory in normal and memory deficit rats."},{"key":"1863_CR249","unstructured":"Foidl N & Makkar H, Becker K. The potential of Moringa oleifera for agricultural and industrial uses Moringa oleifera Webpage. The Miracle Tree: The Multi Uses of Moringa. 45\u201376. https:\/\/www.researchgate.net\/publication\/310440123_The_potential_of_Moringa_oleifera_for_agricultural_and_industrial_uses_Moringa_oleifera_Webpage"},{"key":"1863_CR250","unstructured":"(PDF) Phytochemical analysis and evaluation of antioxidant activities of hydro-ethanolic extract of Moringa oleifera Lam. Pods."},{"key":"1863_CR251","doi-asserted-by":"crossref","unstructured":"Sutalangka C, Wattanathorn J, Muchimapura S, Thukham-Mee W. Moringa oleifera Mitigates Memory Impairment and Neurodegeneration in Animal Model of Age-Related Dementia. Oxid Med Cell Longev. 2013;2013.","DOI":"10.1155\/2013\/695936"},{"key":"1863_CR252","doi-asserted-by":"crossref","unstructured":"Famurewa AC, Aja PM, Nwankwo OE, Awoke JN, Maduagwuna EK, Aloke C. Moringa oleifera seed oil or Virgin coconut oil supplementation abrogates cerebral neurotoxicity induced by antineoplastic agent methotrexate by suppression of oxidative stress and neuro-inflammation in rats. J Food Biochem. 2019;43(3).","DOI":"10.1111\/jfbc.12748"},{"key":"1863_CR253","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.pharmthera.2017.08.010","volume":"182","author":"JG Choi","year":"2018","unstructured":"Choi JG, Kim SY, Jeong M, Oh MS. Pharmacotherapeutic potential of ginger and its compounds in age-related neurological disorders. Pharmacol Ther. 2018;182:56\u201369.","journal-title":"Pharmacol Ther"},{"key":"1863_CR254","doi-asserted-by":"crossref","unstructured":"El Halawany AM, Sayed EL, Abdallah NS, El Dine HM. RS. Retraction note: protective effects of Gingerol on streptozotocin-induced sporadic Alzheimer\u2019s disease: emphasis on Inhibition of \u03b2-amyloid, COX-2, alpha-, beta - secretases and APH1a. Sci Rep. 2023;13(1).","DOI":"10.1038\/s41598-023-36652-w"},{"key":"1863_CR255","unstructured":"Rastogi RP, Mehrotra BN. Compendium of Indian Medicinal Plants, Vol. VI. New Delhi, CDRI Lucknow PID. 1995;4:155\u201363."},{"issue":"3","key":"1863_CR256","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.jep.2007.07.016","volume":"113","author":"M Adams","year":"2007","unstructured":"Adams M, Gm\u00fcnder F, Hamburger M. Plants traditionally used in age related brain disorders\u2013a survey of ethnobotanical literature. J Ethnopharmacol. 2007;113(3):363\u201381.","journal-title":"J Ethnopharmacol"},{"issue":"5","key":"1863_CR257","doi-asserted-by":"publisher","first-page":"593","DOI":"10.4103\/0253-7613.100383","volume":"44","author":"S Bihaqi","year":"2012","unstructured":"Bihaqi S, Singh A, Tiwari M. Supplementation of Convolvulus Pluricaulis attenuates scopolamine-induced increased Tau and amyloid precursor protein (A\u03b2PP) expression in rat brain. Indian J Pharmacol. 2012;44(5):593.","journal-title":"Indian J Pharmacol"}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01863-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-025-01863-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01863-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T16:04:20Z","timestamp":1770307460000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-025-01863-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,23]]},"references-count":257,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["1863"],"URL":"https:\/\/doi.org\/10.1007\/s13346-025-01863-3","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,23]]},"assertion":[{"value":"8 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The author declares that they have provided their consent to publish this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial or other interests that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}